Advertisement

Das v. Willebrand-Jürgens-Syndrom

Chapter
  • 42 Downloads
Part of the Handbuch der Inneren Medizin book series (INNEREN, volume 2 / 9)

Zusammenfassung

Beim v. Willebrand-Jürgens-Syndrom (vWJS) handelt es sich um eine in den meisten Fällen hereditäre, autosomal dominant oder rezessiv vererbte, selten aber auch erworbene hämorrhagische Diathese mit einer quantitativen und/oder qualitativen Störung des als v. Willebrand-Faktor (VIII:vWF) bezeichneten großmolekularen Anteils des Faktor-VIII/v. Willebrand-Faktor-Komplexes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abildgaard CF, Simone JV, Honig GR, Forman EN, Johnson CA, Seeler RA (1968) Von Willebrand’s disease. A comparative study of diagnostic tests. J Pediatr 73: 355Google Scholar
  2. Abildgaard CF, Suzuki Z, Harrison J et al. (1980) Serial studies in von Willebrand’s disease: Variability versus “variants.” Blood 56: 712–716Google Scholar
  3. Achenbach W (1960) Angiohaemophilie. Ergebnisse Innere Med Kinderheilkunde 14: 68Google Scholar
  4. Adashi EY (1980) Lack of improvement in von Willebrand’s disease during pregnancy. N Engl J Med 303: 1178 (letter)Google Scholar
  5. Adelman S, Monto RW, Ponka JL (1972) Surgery in von Willebrand’s disease. Arch Surg 105: 204PubMedGoogle Scholar
  6. Ahr DJ, Hoyer LW, O’Leary DS, Conrad ME (1977) von Willebrand’s disease and hemorrhagic teleangiectasia. Association of two complex disorders of hemostasis resulting in lifethreatening hemorrhage. Am J Med 62: 452Google Scholar
  7. Aihara M, Cooper HA, Wagner RH (1984) Platelet-collagen interactions: increase in rate of adhesion of fixed washed platelets by factor VHI-related antigen. Blood 63: 495–501PubMedGoogle Scholar
  8. Alexander B, Goldstein R (1953) Dual hemostatic defect in pseudohemophilia. J Clin Invest 32: 551Google Scholar
  9. Allain JR, Cooper HA, Wagner RH, Brinkhous KM (1975) Platelets fixed with paraformaldehyde: A new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 85: 318–32Google Scholar
  10. Allain JP, Verroust F, Soulier JP (1980) In vitro and in vivo characterisation of factor VIII preparations. Vox Sang 38: 68–80PubMedGoogle Scholar
  11. Alperin JB (1982) Estrogens and surgery in women with von Willebrand’s disease. Am J Med 73: 367PubMedGoogle Scholar
  12. Ardaillou N, Girma JP, Meyer D, Lavergne JM, Shoa’i I, Larrieu MJ (1978) “Variants” of von Willebrand’s disease. Demonstration of a decreased antigenetic reactivity by immunoradiometric assay. Thromb Res 12: 817–830Google Scholar
  13. Armitage H, Rizza CR (1979) Two populations of factor VIII related antigen in a family with von Willebrand’s disease. Br J Haematol 41: 279–289PubMedGoogle Scholar
  14. Aursness I, Veninga C (1979) Detachment of von Willebrand factor from blood platelets. Thromb Haemost 42: 805Google Scholar
  15. Bachman F (1980) Diagnostic approach to mild bleeding disorders. Semin Hematol 17: 292–30Google Scholar
  16. Barbui T, Rodeghiero F, Dini E (1977) The aspirin tolerance test in von Willebrand’s disease. Thromb Haemost 38: 510–513PubMedGoogle Scholar
  17. Barlow GH, Martin SE, Marder VJ (1984) Sedimentation analysis of von Willebrand and factor VIII C protein using partition cells in the analytical ultracentrifuge. Blood 63: 940–943PubMedGoogle Scholar
  18. Barrow EM, Graham JB (1964) von Willebrand’s disease. Progr Hematol 4: 203Google Scholar
  19. Barrow ES, Reisner HM, Graham JB (1979) The separation of Willebrand factor from factor VIII related antigen. Br J Haematol 42: 455–468PubMedGoogle Scholar
  20. Barrowcliffe TW, Kemball-Cook G, Morris G et al. (1981) Factor VHI-related activities in therapeutic concentrates. J Lab Clin Med 97: 429–438PubMedGoogle Scholar
  21. Baumgartner HR (1973) The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Micro vase Res 5: 167–179Google Scholar
  22. Baumgartner HR, Tschopp TB, Meyer D (1980) Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor. Br J Haematol 44: 127–139PubMedGoogle Scholar
  23. Bennett B, Ratnoff OD (1972) Changes in antihemophilic factor ( AHF, factor VIII) procoagulant activity and AHF-like antigen in normal pregnancy, and following exercise and pneumoencephalographie. J Lab Clin Med 80: 256Google Scholar
  24. Bennett B, Ratnoff OD, Levin J (1972) Immunologic studies in von Willebrand’s disease. Evidence that the antihemophilic factor ( AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia. J Clin Invest 51: 2597–2601Google Scholar
  25. Bennett E, Dormandy K (1966) Pool’s cryoprecipitate and exhausted plasma in the treatment of von Willebrand’s disease and factor XI deficiency. Lancet 11: 731–732Google Scholar
  26. Biggs R, Matthews JM (1963) The treatment of haemorrhage in von Willebrand’s disease and the blood level of factor VIII ( AHF ). Br J Haematol 9: 203Google Scholar
  27. Bird P, Rizza CR (1975) A method for detecting factor VIII clotting activity associated with factor VHI-related antigen in agarose gels. Br J Haematol 31: 5 — 12PubMedGoogle Scholar
  28. Biggs R, Rizza CR (1978) The control of haemostasis and hemophilic patients. In: Biggs R (ed) The treatment of haemophilia A and B and von Willebrand’s disease. Blackwell Scientific Publ, Oxford, p 127Google Scholar
  29. Björlin G, Nilsson IM (1973) Tooth extractions in hemophiliacs after administration of a single dose of factor VIII or factor IX concentrate supplemented with AMCA. Oral Surg, Oral Medicine, Oral Pathology 36: 482–489Google Scholar
  30. Blatt PM, Brinkhous KM, Culp HR et al. (1976) Antihemophilic factor concentrate therapy in von Willebrand’s disease. Dissociation of bleeding time factor and ristocetincofactor activities. JAMA 236: 2770–277PubMedGoogle Scholar
  31. Blättler W, Jacky E, Müller M, Graf M (1979) Der Einfluß von l-Desamino-8-D-Arginine-Vasopressin ( DD A VP) auf die Blutgerinnung bei Patienten mit Haemophilie A und gesunden Männern. Schweiz Med Wochenschr 109: 1367Google Scholar
  32. Blättler W, Graf M, Jacky E, Müller M (1980) The kinetics of factor VIII upon l-deamino-D-arginine-vasopressin (DD A VP) in hemophiliacs and normal men. In: Sutor AH (ed) DD A VP in bleeding disorders. 1st Int Symp on DDAVP in bleeding disorders, Münster 79. Schattauer, Stuttgart New York, p 52Google Scholar
  33. Blombäck B, Blombäck M (1956) Purification of human and bovine fibrinogen. Ar Kir Kemi 10: 415Google Scholar
  34. Blomback M, Jorpes J, Nilsson IM (1963) von Willebrand’s disease. Am J Med 34: 236–241Google Scholar
  35. Bloom AL (1977) Physiology of factor VIII. In: Poller L (ed) Recent advances in blood coagulation, 2nd edn. Churchill Livingstone, Edinburgh, pp 141–181Google Scholar
  36. Bloom AL (1979) The biosynthesis of factor VIII. Clin Haematol 8: 53–77PubMedGoogle Scholar
  37. Bloom AL (1980) The von Willebrand Syndrome. Semin Hematol XVII: 215–227Google Scholar
  38. Bloom AL, Peake IR (1977) Molecular genetics of factor VIII and its disorders. Semin Hematol 14: 319–33PubMedGoogle Scholar
  39. Bloom AL, Peake IR (1979) Apparent “Dominant” and “Recessive” inheritance of von Willebrand’s disease within the same kindreds. Possible biochemical mechanisms. Thromb Res 15: 505–512Google Scholar
  40. Bloom AL, Giddings JC, Wilks CJ ( 1973 a) Factor VIII on the vascular intima: Possible importance in haemostasis and thrombosis. Nature 241: 217–219Google Scholar
  41. Bloom AL, Peake IR, Giddings JC (1973 b) The presence and reactions of high and lower molecular weight procoagulant factor VIII, in the plasma of patients with von Willebrand’s disease after treatment; significance for a structural hypothesis for factor VIII. Thromb Res 3: 389Google Scholar
  42. Bloom AL, Peake IR, Giddings JD et al. (1976) Endothelial cells and factor Vlll-related protein. Lancet 1: 46PubMedGoogle Scholar
  43. Bloom AL, Peake IR, Furlong RA et al. (1979) High potency factor VIII concentrate: More effective than cryoprecipitate in a patient with von Willebrand’s disease and inhibitor. Thromb Res 16: 847–85PubMedGoogle Scholar
  44. Bolhuis PA, Sakariassen KS, Sixma J J (1979) Adhesion of blood platelets to human arterial subendothelium: Role of factor VIII-von Willebrand factor. Haemostasis 8: 312–323Google Scholar
  45. Bolhuis PA, Sakariassen KS, Sander HJ et al. (1981) Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 97: 568PubMedGoogle Scholar
  46. Borchgrevink CF (1960) A method for measuring platelet adhesiveness in vivo. Acta Med Scand 168: 157Google Scholar
  47. Borchgrevink CF, Waaler BA (1958) The secondary bleeding time. A new method for the differentiation of hemorrhagic diseases. Acta Med Scand CLXII: 361–374Google Scholar
  48. Borchgrevink CF, Egeberg O, Godal HC, Hjort PF (1963) The effect of plasma and Cohn’s fraction I on the Duke and Ivy bleeding times in von Willebrand’s disease. Acta Med Scand 173: 235PubMedGoogle Scholar
  49. Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927PubMedGoogle Scholar
  50. Böttcher D, Hasler K, Winckelmann G, Sutor AH, Mair D (1978) Zur Diagnostik des von Willebrand Jürgens Syndroms. Med Klin 73: 833–838PubMedGoogle Scholar
  51. Böttcher D, Hasler K, Schmidt B, Winckelmann G (1980) Diagnostische Wertigkeit der Ristocetin-Cofaktor-Bestimmung. In: Voss H von, Göbel U (Hrsg) Praktische Anwendung der Thrombozytenfunktionsdiagnostik. Thieme, Stuttgart, S 156Google Scholar
  52. Bouma BN, Wiegerinck Y, Sixma JJ et al. (1972) Immunological characterization of purified antihaemophilic factor A (factor VIII) which corrects abnormal platelet retention in von Willebrand’s disease. Nature 236: 104 - 106Google Scholar
  53. Bowie EJW, Owen CA Jr, Thompson JH Jr, Didisheim P (1969) Platelet adhesiveness in von Willebrand’s disease. Am J Clin Pathol 52: 69–77PubMedGoogle Scholar
  54. Bowie EJW, Owen CA Jr, Zollman PE (1973) Tests of hemostasis in swine: Normal values and values in pigs affected with von Willebrand’s disease. Am J Vet Res 34: 1405–1407Google Scholar
  55. Bowie EJW, Fass DN, Olson JD, Owen CA Jr (1974) Transfusion and autotransfusion of plasma in von Willebrand’s disease. Thromb Res 5: 479Google Scholar
  56. Bowie EJW, Fass DN, Olson JD, Owen CA (1976) The spectrum of von Willebrand’s disease revisited. Mayo Clin Proc 51: 35PubMedGoogle Scholar
  57. Bowie EJW, Fass DN, Owen CA Jr (1980) Hemostatic effect of transfused Willebrand factor in porcine von Willebrand’s disease. Haemostasis 9: 352–365PubMedGoogle Scholar
  58. Bowie EJW, Fass DN, Katzmann JA (1981) The effect of antiporcine Willebrand factor monoclonal antibodies on the bleeding time. Thromb Haemost 46: 166 (abstract)Google Scholar
  59. Brinkhous KM, Read MS (1978) Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying freezing, or lyophilization: New stable platelet preparations for von Willebrand factor assays. Thromb Res 13: 591–597Google Scholar
  60. Brinkhous KM, Read MS (1980) Use of venom coagglutinin and lyophilized platelets in testing for plateletaggregating von Willebrand factor. Blood 55: 517–520PubMedGoogle Scholar
  61. Brinkhous KM, Graham JE, Cooper HA, Allain JP, Wagner RH (1975) Assay of von Willebrand factor in von Willebrand’s disease and hemophilia: Use of a macroscopic platelet aggregation test. Thromb Res 6: 267–272Google Scholar
  62. Brinkhous KM, Barnes DS, Potter JY, Read MS (1981) Von Willebrand syndrome induced by a Bothrops venom factor: Bioassay for venom coagglutinin. Proc Natl Acad Sei 78: 3230–3234Google Scholar
  63. Brockway WJ, Fass DN (1977) The nature of the interaction between ristocetin-Willebrand factor and the factor VIII coagulant activity molecule. J Lab Clin Med 89: 1295–1305PubMedGoogle Scholar
  64. Brody JI (1975) Prolonged bleeding times with factor IX and XI deficiency (von Willebrand Syndromes). Am J Med Sei 269: 19Google Scholar
  65. Brown JE, Baugh RF, Hougie C (1979) Effect of exercise on the factor VIII complex: A correlation of the von Willebrand antigen and factor VIII coagulant antigen increase. Thromb Res 15: 61–6Google Scholar
  66. Buchanan GR, Green DM, Handin RI (1977 a) Combined von Willebrand disease and Hageman factor deficiency. J Pediatr 90: 779Google Scholar
  67. Buchanan GR, Martin V, Levine PH, Scoon K, Handin RI (1977b) The effects of “antiplatelet” drugs on bleeding time and platelet aggregation in normal human subjects. Am J Clin Pathol 68: 355–35PubMedGoogle Scholar
  68. Buchanan JC, Leavell BS (1956) Pseudohemophilia: Report of 13 men cases and statistical review of previously reported cases. Ann Intern Med 44: 241PubMedGoogle Scholar
  69. Budde U, Brackmann HH, Etzel F (1980) Einsatz von DDAVP bei zahnärztlichen Eingriffen bei Patienten mit von Willebrand Syndrom und einem Patienten mit kombiniertem Herzmansky-Pudlak-Syndrom und leichtem von Willebrand Syndrom. In: Sutor AH (ed) DDAVP in bleeding disorders (1st Int Symp on DDAVP in bleeding disorders, Münster 1979 ). Schattauer, Stuttgart New York, p 148Google Scholar
  70. Budde U, Schäfer G, Müller N, Hammerstein U, Lüchters G (1982) Vorkommen milder Formen des von Willebrand Syndroms Typ I in der „Normalbevölkerung“. In: Loo J van de, Asbeck F (Hrsg) Hämostase, Thrombophilie und Arteriosklerose, (Berichtband 2. Kongreß für Thrombose und Hämostase). Schattauer, Stuttgart New York, S 505Google Scholar
  71. Budde U, Schäfer G, Müller N et al. (1984) Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood 64: 981–985PubMedGoogle Scholar
  72. Caduff T, Straub P (1979) Die Verwendung gefrorener Thrombozyten für die Bestimmung des von Willebrand Faktors mit Ristocetin. Schweiz Med Wochenschr 109: 399PubMedGoogle Scholar
  73. Caen J, Larrieu MJ, Meyer D (1969) Diagnostic et traitement de la Maladie de Willebrand. Rev Med Suisse Romande 89: 67PubMedGoogle Scholar
  74. Caen JP, Nurden AT, Jeanneau C, Michel H, Tobelem G, Levy-Toledano S, Sultan Y, Valensi F, Bernard J (1976) Bernard-Soulier Syndrome: a new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII/von Willebrand protein. J Lab Clin Med 87: 586–596Google Scholar
  75. Chediak JR, Telfer MC, Green D (1977) Platelet function and immunologic parameters in von Willebrand’s disease following cryoprecipitate and factor VIII concentrate infusion. Am J Med 62: 369PubMedGoogle Scholar
  76. Chediak JR, Lambert E, Johnson EI, Telfer MC (1980) Combined severe factor XI deficiency and von Willebrand’s disease. Am J Clin Pathol 74: 108PubMedGoogle Scholar
  77. Chesney C, Colmon RW, Pechet L (1974) A syndrome of platelet-release abnormality and mild hemophilia. Blood 43: 821PubMedGoogle Scholar
  78. Clemetson KJ, Lüscher EF (1985) Glykoproteine der Plättchenmembran. Haemostaseologie, im DruckGoogle Scholar
  79. Cockburn CG, Beaufre-Apps RJ de, Wilson J, Hardisty RM (1981) Parallel destruction of factor VIII procoagulant activity and an 85,000-dalton protein in highly purified factor VIII/vWF. Thromb Res 21: 295–30PubMedGoogle Scholar
  80. Cohen JA (1972) Multiple congenital anomalies: the association of seven defects including multiple exostoses, von Willebrand’s disease, and bilatoral winged scapula. Arch Intern Med 129: 972PubMedGoogle Scholar
  81. Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) Studies with a murine monoclonal antibody that abolishes Ristocetin-induced binding of von Willebrand factor to platelets: Additional evidence in support of von GPIb as a platelet receptor for von Willebrand factor. Blood 61: 99–110Google Scholar
  82. Conlon CL, Weinger RS, Cimo PL, Moak JL, Olson JD (1978) Teleangiectasia and von Willebrand’s disease in two families. Ann Intern Med 89: 921PubMedGoogle Scholar
  83. Cooper HA, Mason RG, Brinkhous KM (1976) The platelet: Membrane and surface reactions. Ann Rev Physiol 38: 501Google Scholar
  84. Corder MP, Culp NW, Barrett O Jr (1973) Familial occurrence of von Willebrand’s disease, thrombocytopenia, and severe gastrointestinal bleeding. Am J Med Sei 265: 219Google Scholar
  85. Cornu P (1965) Maladie de Willebrand. Pathol Biol (Paris) 13: 546Google Scholar
  86. Cornu P, Larrieu MJ, Caen J, Bernard J (1961) Maladie de Willebrand. Etude clinique, genetique et biologique. Nouv Rev Fr Hematol 1: 231Google Scholar
  87. Cornu P, Larrieu MJ, Caen J, Bernard J (1963) Transfusion studies in von Willebrand’s disease: Effect on bleeding time and factor VIII. Br J Haematol 9: 189–202Google Scholar
  88. Counts RB (1975) Solid-phase immunoradiometric assay of factor VIII protein. Br J Haematol 31: 429–43PubMedGoogle Scholar
  89. Counts RB, Paskell SL, Elgee SK (1978) Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor. J Clin Invest 62: 702–709PubMedGoogle Scholar
  90. Cramer AD, Melaragno AJ, Phifer SJ, Hougie C (1976) Von Willebrand disease San Diego, a men variant. Lancet 11: 12–1Google Scholar
  91. Crefeld S van, Kloosterman GJ, Mochtar IA, Koppe JG (1962) Interchange between blood of mother and fetus in vascular hemophilia. Biol Neonat 4: 173Google Scholar
  92. Czapek EE, Deykin D, Salzman E et al. (1978) Intermediate syndrome of platelet dysfunction. Blood 52: 103–13PubMedGoogle Scholar
  93. Davies BL, Furlong RA, Peake IR (1981) Studies on the relationship between factor VHI-related antigen (VIIIRAg) and factor VIII clotting antigen (VIIICAg) by immunoelectrophoresis and autoradiography using 125 J anti-VIIICAg. Thromb Res 22: 87–96Google Scholar
  94. Donati MB, de Gaetano G, Vermylen J (1973) Evidence that bovine factor VIII, not bovine fibrinogen aggregates human platelets. Thromb Res 2: 97–104Google Scholar
  95. Doucet-de Bruine MHM, Sixma JJ, Over J, Beeser-Visser NH (1978) Heterogeneity of human factor VIII binding to platelets in the presence of ristocetin. J Lab Clin Med 92: 96–107Google Scholar
  96. Dowling SV, Müntz RH, D’Souza S, Ekert H (1976) Platelet release abnormality associated with a variant of von Willebrand’s disease. Blood 47: 265PubMedGoogle Scholar
  97. Dudley NE, Kernoff PBA, Gough MH (1971) Surgery in children with congenital disorders of blood coagulation. J Pediatr Surg 6: 689PubMedGoogle Scholar
  98. Duke WW (1910) The relation of blood platelets to hemorrhagic disease. JAMA 55: 1185–1192Google Scholar
  99. Egberg N, Blombäck M (1976) On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand’s disease. Thromb Res 9: 527–531PubMedGoogle Scholar
  100. Egeberg O (1965) An inherited hemorrhagic trait with characteristics resembling both mild hemophilia of type A and von Willebrand’s disease. Scand J Clin Lab Invest [Suppl] 84: 25Google Scholar
  101. Ekert H, Chavin SI (1977) Changes in electrophoretic mobility of human factor VIII related antigen: Evidence for a subunit structure. Br J Haematol 36: 271–279Google Scholar
  102. Elston RC, Graham JB, Miller CH, Reisner HM, Bouma BN (1976) Probalistic classification of haemophila A carriers by discriminant analysis. Thromb Res 8: 683PubMedGoogle Scholar
  103. Eriksson AW (1961) Eine neue Blutersippe mit von Willebrand Jürgens’sche Krankheit (erbliche Thrombopathie) auf Äland (Finnland). Acta Gen Med (Roma) 10: 157–180Google Scholar
  104. Esham RH, Skilling FC Jr, Dodson WH, Hammack WJ (1974) Hereditary hemorrhagic teleangiectasia and factor VIII deficiency. Arch Intern Med 134: 327PubMedGoogle Scholar
  105. Evans RJ, Austen DEG (1977) Assay of ristocetin cofactor using fixed platelets and a platelet counting technique. Br J Haematol 37: 289–294PubMedGoogle Scholar
  106. Eyster ME, Ballard JO, Prager D (1978) Comparison of factor VIII levels after adrenalin in classic hemophilia and von Willebrand’s disease (vWD). Thromb Haemostas 39: 657–662Google Scholar
  107. Fasching I, Niessner H (1982) Aufgrund welcher Ereignisse wurde die Diagnose eines vWJS gestellt. Haemophilie Symposion HamburgGoogle Scholar
  108. Fass DN, Brockway WJ, Owen CA, Bowie EJW (1976) Factor VIII ( Willebrand) antigen and ristocetin-Willebrand factor in pigs with von Willebrand’s disease. Thromb Res 8: 319Google Scholar
  109. Fass DN, Knutson GJ, Bowie EJW (1978) Porcine Willebrand factor: A population of multimers. J Lab Clin Med 91: 307–320Google Scholar
  110. Fass DN, Bowie EJW, Owen CA Jr, Zollman PE (1979) Inheritance of porcine von Willebrand’s disease: study of a kindred of over 700 pigs. Blood 53: 712–719PubMedGoogle Scholar
  111. Fass DN, Knutson GJ, Katzmann JA (1982) Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 59: 594–600PubMedGoogle Scholar
  112. Finlay TH, Marcus D, Kowalski D, Silber P (1981) Interaction of porcine von Willebrand factor (platelet aggregating factor) with human platelets. Biochim Biophys Acta 672: 79–88PubMedGoogle Scholar
  113. Forbes CD, Prentice CRM (1973) Aggregation of human platelets by purified porcine and bovine antihaemophilic factor. Nature 241: 149–150Google Scholar
  114. Fuhge P, Braun K, Heimburger N (1982) Neues Reagenz für die Bestimmung des Ristocetin-Cofak-tors, Faktor VIIIR:Cof. In: Loo J van de, Asbeck F (Hrsg) Hämostase, Thrombophilie und Arteriosklerose, (Berichtband 2. Kongreß für Thrombose und Hämostase) Schattauer, Stuttgart New York, S 700Google Scholar
  115. Fujimoto T, Hawiger J (1982) Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature 297: 154PubMedGoogle Scholar
  116. Fujimoto T, Ohara S, Hawiger J (1982) Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets. J Clin Invest 69: 1212PubMedGoogle Scholar
  117. Fukui H, Mikami S, Takase T, Fujimura Y, Nishino M, Yoshioka A (1980) Patterns of factor VIII related antigen on crossed immunoelectrophoresis and large pore Polyacrylamide gel-crossed immunoelectrophoresis in von Willebrand’s disease. Br J Haematol 46: 269PubMedGoogle Scholar
  118. Fulcher CA, Zimmerman TS (1982) Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 79: 1648–1652PubMedGoogle Scholar
  119. Fulcher CA, Ruggeri ZM, Zimmerman TS (1983) Isoelectric focusing of human von Willebrand factor in Urea-agarose gels. Blood 61: 304–310PubMedGoogle Scholar
  120. Furlan M, Beck EA (1977) Degradation of purified factor VIII by endogeneous contaminating enzymes. Thromb Res 10: 153–158PubMedGoogle Scholar
  121. Fuster V, Bowie EJW (1978) The von Willebrand pigs as a model for atherosclerosis research. Thromb Haemostas 39: 322–327Google Scholar
  122. Fuster V, Bowie EJW, Lewis JC (1978) Resistance to arteriosclerosis in pigs with von Wille-brand’s disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 61: 722–73Google Scholar
  123. Gader AMA, Costa J da, Cash JD (1973) A new vasopressin analogue and fibrinolysis. Lancet 11: 1417–141Google Scholar
  124. Gaetano G de, Donati MB, Vermylen J (1974) Evidence that human platelet aggregating activity in porcine plasma is a property of von Willebrand factor. Thromb Diathes Haemorrh 32: 549–55Google Scholar
  125. Garcia VV, Silva JA, Borrasca AL (1982) Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factor V and VIII). Thromb Haemostas 48: 91–93Google Scholar
  126. Gastaldi G, Rasore-Quartino A, Galletti A, Campanella A, Barone E, Mannucci PM (1978) Coexistence of haemophilia A and von Willebrand’s disease in the same kindred. Scand J Haematol 20: 423PubMedGoogle Scholar
  127. Geiger MT, Rath CE (1963) Occurence of two hemorrhagic disorders with antihemophilic factor (AHF) deficiency in the same family: classical hemophilia and von Willenbrand’s disease. J Lab Clin Med 61: 424PubMedGoogle Scholar
  128. George JN, Onofre AR (1982) Human platelet surface binding of endogenous secreted factor VIII-von Willebrand factor and platelet factor 4. Blood 59: 194–197PubMedGoogle Scholar
  129. George JN, Nurden AT, Phillips DR (1984) Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 311: 1084–1098PubMedGoogle Scholar
  130. Giddings JC (1980) Hereditary coagulation disorders: laboratory techniques. In: Thomson JM (ed) Blood coagulation and haemostasis, a practical guide, 2nd edn. Churchill, Livingstone Eding-burgh, pp 117–15Google Scholar
  131. Giddings JC, Evans DJ, Bloom AL (1979) Quantitation of factor VIII related antigen ( FVIII-RAG) using a laser nephelometer. Thromb Res 15: 847Google Scholar
  132. Gilchrist GS, Hagedorn AB, Owen CA Jr, Bowie EJW (1980) Management of patients with von Willebrand’s disease undergoing surgical procedures. In: Mammen EF, Barnhart MI, Lusher JM, Walsh RT (eds) Treatment of bleeding disorders. PJD Publications limited Westbury/NY 11590, p 83Google Scholar
  133. Girma JP, Ardaillou N, Meyer D et al. (1979) Fluid phase immunoradiometric assay for the detection of qualitative abnormalities of factor VIII/von Willebrand factor in variants of von Willebrand’s disease. J Lab Clin Med 93: 926–939PubMedGoogle Scholar
  134. Graham JB (1979) Genotype assignment (carrier detection) in the hemophilias. Clin Haematol 8: 115–14PubMedGoogle Scholar
  135. Gralnick HR (1978) Factor VIII/von Willebrand factor protein galactose, a cryptic determinant of von Willebrand factor activity. J Clin Invest 62: 496–499PubMedGoogle Scholar
  136. Gralnick HR, Coller BS, Sultan Y (1975) Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand’s disease. J Clin Invest 56: 814–827Google Scholar
  137. Gralnick HR, Coller BR, Sultan Y (1976) Carbohydrate deficiency of the factor VIII von Willebrand protein in von Willebrand’s disease variants. Science 192: 56–59PubMedGoogle Scholar
  138. Gralnick HR, Coller BS, Shulman NR et al. (1977a) Factor VIII. Ann Intern Med 86: 598–616Google Scholar
  139. Gralnick HR, Sultan Y, Coller BS ( 1977 b) von Willebrand’s disease. Combined qualitative and quantitative abnormalities. N Engl J Med 296: 1024–1030Google Scholar
  140. Gralnick HR, Williams SB, Morisato DK (1981a) Effect of the multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood 58: 387–397PubMedGoogle Scholar
  141. Gralnick HR, Williams SB, Shafer B, Corash L (1981b) von Willebrand’s disease (vWd) with normal ristocetin-induced platelet aggregation (RIPA); abnormal platelets and abnormal factor VIII/von Willebrand factor (FVIII/VWF) protein. Blood [Suppl 1] 58:193 aGoogle Scholar
  142. Gralnick HR, Cregger MC, Williams SB (1982 a) Characterization of the defect of the factor VIII/von Willebrand factor protein in von Willebrand’s disease. Blood 59: 542–548Google Scholar
  143. Gralnick HR, Williams SB, Shafer BC, Corash L (1982b) Factor VIII/von Willebrand factor binding to von Willebrand’s disease platelets. Blood 60: 328–332PubMedGoogle Scholar
  144. Gralnick HR, Williams S, Rick M (1983) The role of Carbohydrate in the maintainance of the multimeric structure of the factor VIII/vWF protein. Thromb Haemostas 50: 318 (abstract)Google Scholar
  145. Green D (1979) Role of the von Willebrand factor in atherogenesis. Artery 5: 262–272PubMedGoogle Scholar
  146. Green D, Potter EV (1976 a) Failure of AHF concentrate to control bleeding in von Willebrand’s disease. Am J Med 60: 357–360Google Scholar
  147. Green D, Potter EV (1976b) Platelet bound ristocetin aggregating factor in normal subjects and patients with von Willebrand’s disease. J Lab Clin Med 87: 976PubMedGoogle Scholar
  148. Green D, Reynolds N (1977) Double-antibody radioimmunoassay for factor VHI-related antigen. Clin Chem 23: 1648–1653PubMedGoogle Scholar
  149. Griggs TR, Cooper HA, Webster WF, Wagner RH, Brinkhous KM (1973) Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand factors. Proc Natl Acad Sei USA 70: 2814Google Scholar
  150. Griggs TR, Webster WP, Cooper HA (1974) von Willebrand factor: Gene dosage relationships and transfusion response in bleeder swine-A new bioassay. Proc Natl Acad Sei USA 71: 2087–209Google Scholar
  151. Griggs TR, Potter J, McClanahan SB, Webster WB, Brinkhous KM (1977) Macromolecular factor VIII complex: Functional and structural heterogeneity observed in von Willebrand swine with transfusion. Proc Natl Acad Sei USA 74: 759–763Google Scholar
  152. Griggs TR, Reddick RL, Sultzer D, Brinkhous KM (1981) Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand’s disease. Am J Pathol 102: 137–145PubMedGoogle Scholar
  153. Gross R, Mammen E (1958) Über Pseudohaemophilie, Angiohaemophilie, von Willebrand Jürgens-’sche Krankheit und verwandte hämorrhagische Diathesen. Klin Wochenschr 36: 112Google Scholar
  154. Hagedorn AB (1971) Von Willebrand’s disease. JAMA 216: 991PubMedGoogle Scholar
  155. Hampton JW, Shinada S, Drummond M (1980) Von Willebrand’s disease: Perspectives in treatment. In: Mammen EF, Barnhart MI, Lusher JM, Walsh RT (eds) Treatment of bleeding disorders. PJD Publications Limited Westbury/NY 11590, p 71Google Scholar
  156. Handin RI, Moloney WC (1974) Antibody-induced von Willebrand’s disease. Blood 44: 933Google Scholar
  157. Handin RI, Martin V, Moloney WC (1976) Antibody-induced von Willebrand’s disease: A newly defined inhibitor syndrome. Blood 48: 393Google Scholar
  158. Hanna W, McCarroll D, McDonald T, Painter P, Tuller J, Chen J, Lange R (1981) Variant von Willebrand’s disease and pregnancy. Blood 58: 873PubMedGoogle Scholar
  159. Harrison RL, McKee PA (1984) Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 63: 657–665PubMedGoogle Scholar
  160. Hartmann W, Henning J (1982) Die Qualität von F-VIII-Konzentraten auf dem deutschen Arzneimittelmarkt. Die Ortskrankenkasse 64: 1–13Google Scholar
  161. Hawiger J, Fujimoto T, Ohara S (1981) The contrasting effect of thrombin and prostacyclin on availability of the receptor for factor VIIIVWF on human platelets. Clin Res 29: 571AGoogle Scholar
  162. Heimburger N, Schwinn H, Kumpe G, Herchenhan B (1977) F VIII-Konzentrate-Fortschritte in der Entwicklung. Pharmazeutische Zeitung 122: 1382Google Scholar
  163. Hellem AJ (1970) Platelet adhesiveness in von Willebrand’s disease. A study with a new modification of the glass bead filter method. Scand J Haematol 7: 374PubMedGoogle Scholar
  164. Hill C, Taylor J J (1968) von Willebrand’s disease in obstetrics and gynaecology. J Obstet Gyn Brit Cwlth 75: 453Google Scholar
  165. Hill FGH, Enoyat MS, George AJ (1983) Investigation including VIIIR:Ag multimeric analysis of a large kindred with type IIA von Willebrand’s disease showing a dominant inheritance and similar gene expression in four generations. Thromb Haemostas 50: 735–739Google Scholar
  166. Holland L, Adamson A, Ingram GIC, Chalmers DG (1980) Acquired von Willebrand’s syndrome. Short communication. Br J Haematol 45: 161–164Google Scholar
  167. Holmberg L, Nilsson IM (1972) Genetic variants of von Willebrand’s disease. Br Med J 111: 317–32Google Scholar
  168. Holmberg L, Nilsson IM (1974) AHF related protein in clinical praxis. Scand J Haematol 10: 12–16Google Scholar
  169. Holmberg L, Nilsson IM (1979) VIIIR:Ag in platelets from patients with various forms of von Willebrand’s disease. Thromb Haemostas 42: 1033Google Scholar
  170. Holmberg L, Mannucci PM, Turesson I et al. (1974) Factor VIII antigen in the vessel walls in von Willebrand’s disease and hemophilia. Scand J Haematol 13: 33–38PubMedGoogle Scholar
  171. Holmberg L, Borge L, Nilsson IM (1981) Factor VIII:C and VIIICAg response in a patient with haemophilia A and von Willebrand’s disease after administration of different factor VIII concentrates or plasma. Br J Haematol 47: 587PubMedGoogle Scholar
  172. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjörin E (1983) Platelet aggretation induced by l-desamino-d-arginine Vasopressin ( DDAVP) in Type IIB von Willebrand’s disease. N Engl J Med 309: 816Google Scholar
  173. Howard MA, Firkin BG (1971) Ristocetin-A new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 26: 362–369PubMedGoogle Scholar
  174. Howard MA, Sawers RJ, Firkin BG (1973) Ristocetin: A means of differentiating von Willebrand’s disease into two groups. Blood 41: 687–690Google Scholar
  175. Howard MA, Montgomery DC, Hardisty RM (1974) Factor VHI-related antigen in platelets. Thromb Res 4: 617–62PubMedGoogle Scholar
  176. Howard MA, Hendrix L, Firkin BG (1979) Further studies on the factor VIII of a patient with a variant form of von Willebrand’s disease. Thromb Res 14: 609–619PubMedGoogle Scholar
  177. Howard MA, Salem HH, Thomas KB et al. (1982) Variant von Willebrand’s disease type B-revisited. Blood 60: 1420–142PubMedGoogle Scholar
  178. Hoyer LW (1972) Immunological studies of antihemophilia factor (AHF, factor VIII). IV. Radioimmunoassay of AHF antigen. J Lab Clin Med 80: 822–833PubMedGoogle Scholar
  179. Hoyer LW (1981) The factor VIII complex: Structure and function. Blood 58: 1–13PubMedGoogle Scholar
  180. Hoyer LW (1982) The Assessment of von Willebrand’s disease. In: Bloom AL (ed) The hemophilias. Methods in hematology, vol 5. Churchill Livingstone, Edinburgh London Melbourne New York, pp 106–12Google Scholar
  181. Hoyer LW, Shainoff JR (1980) Factor VHI-related protein circulates in normal human plasma as high molecular weight multimers. Blood 55: 1056–1059PubMedGoogle Scholar
  182. Hoyer LW, Trabold NC (1981) The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation. J Lab Clin Med 97: 50–64Google Scholar
  183. Hoyer LW, Santos RP de los, Hoyer JR (1973) Antihemophilic factor antigen: Localization in endothelial cells by immunofluorescent microscopy. J Clin Invest 52: 2737–2744Google Scholar
  184. Hoyer LW, Rizza CR, Tuddenham EGD, Carta CA, Armitage H, Rotblat F (1983) Von Willebrand factor multimer patterns in von Willebrand’s disease. Br J Haematol 55: 493PubMedGoogle Scholar
  185. Ingram GIC (1978) Classification of von Willebrand’s disease. Lancet 11: 1364Google Scholar
  186. Ingram GIC, Kingston PJ, Leslie J et al. (1971) Four cases of acquired von Willebrand’s syndrome. Br J Haematol 21: 189PubMedGoogle Scholar
  187. Ingram GIC, Prentice CRM, Forbes CD et al. (1973) Low factor VHI-like antigen in acquired von Willebrand’s syndrome and response to treatment. Br J Haematol 25: 137PubMedGoogle Scholar
  188. Italian Working Group (1977) Spectrum of von Willebrand’s disease: A study of 100 cases. Br J Haematol 35: 101–11Google Scholar
  189. Ivy AC, Nelson D, Bucher G (1941) The standardization of certain factors in the cutaneous “venostasis” bleeding time technique. J Lab Clin Med 26: 1812–1822Google Scholar
  190. Jaffe EA, Hoyer LW, Nachman RL (1973) Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 52: 2757–2764PubMedGoogle Scholar
  191. Jaffe EA, Hoyer LW, Nachman RL (1974) Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sei USA 71: 1906–1909Google Scholar
  192. Jakab T, Pflugshaupt R, Furlan M, Beck EA (1978) Variable degradation of factor VHI-related protein in lyophilised concentrates of antihaemophilic factor ( AHF ). Vox Sang 35: 36Google Scholar
  193. Jenkins CSP, Meyer D, Larrieu MJ (1976 a) Interaction of ristocetin and von Willebrand factor. Thromb Haemostas 35: 752–753Google Scholar
  194. Jenkins CSP, Phillips DR, Clemetson KJ (1976b) Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand’s disease. J Clin Invest 57: 112–124Google Scholar
  195. Johnson AJ, Karpatkin MH, Newman J (1971) Clinical investigation of intermediate and high-purity antihaemophilic factor (factor VIII) concentrates. Br J Haematol 21: 21PubMedGoogle Scholar
  196. Joist HJ, Cowan JF, Zimmerman TS (1978) Acquired von Willebrand’s disease: Evidence for a quantitative and qualitative factor VIII disorder. N Engl J Med 298: 988–991Google Scholar
  197. Jürgens J (1969) Zur Klinik der von Willebrand Jürgens Syndrome. Hämat und Bluttransfusion 6: 164Google Scholar
  198. Jürgens R, Lehmann W, Wegelius D (1957) Mitteilung über Mängel an antihaemophilem Globulin ( Faktor VIII) bei der Aalandischen Thrombopathie (von Willebrand Jürgens ). Thromb Diath Haemorrh 1: 257–260Google Scholar
  199. Kalogjera V, Owen WG (1978) Identity of bovine platelet aggregating factor and ristocetin-Willebrand factor. Thromb Res 13: 857PubMedGoogle Scholar
  200. Kao KJ, Pizzo SV, McKee P (1979 a) Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. J Clin Invest 63: 656–664Google Scholar
  201. Kao KJ, Pizzo SV, McKee P (1979b) Platelet receptors for human factor VIII/von Willebrand factor protein: Functional correlation of receptor occupancy and ristocetin-induced platelet aggregation. Proc Natl Acad Sei USA 76: 5317–5320Google Scholar
  202. Kasper CK, Hoag MS, Aggeier PM, Stone S (1964) Blood clotting factors in pregnancy: factor VIII concentrations in normal and AHF-deficient women. Obstet Gynecol 24: 242PubMedGoogle Scholar
  203. Kass L, Ratnoff OD, Leon MA (1969) Studies on the purification of antihemophilic factor (factor VIII). I. Precipitation of antihemophilic factor by concanavalin A. J Clin Invest 48: 351–358Google Scholar
  204. Katzmann JA, Mujwid DK, Miller RS, Fass DN (1981) Monoclonal antibodies to von Willebrand’s factor: Reactivity with porcine and human antigens. Blood 58: 530–535Google Scholar
  205. Kelton JG, Bishop J, Carter CJ, Hirsh J (1980) A comparison of the quantitative ristocetin von Willebrand factor assay by using fresh and fixed platelets. Thromb Res 18: 477–483PubMedGoogle Scholar
  206. Kernoff LM, Rose AG, Hughes J, Jacobs P (1981) Autopsy findings in an elderly man suffering from severe von Willebrand’s disease. Thromb Haemostas 46: 714Google Scholar
  207. Kernoff PBA, Gruson R, Rizza CR (1974) A variant of factor VHI-related antigen. Br J Haematol 26: 435–44PubMedGoogle Scholar
  208. Kessler CM, Floyd CM, Rick ME et al. (1984) Collagen-factor VIII/von Willebrand factor protein interaction. Blood 63: 1291–1298PubMedGoogle Scholar
  209. Kinoshita S, Harrison J, Lazerson J, Abildgaard Ch (1984) A new variant of dominant type II von Willebrand’s disease with aberrant multimeric pattern structure of factor VHI-related antigen, ( Type II D ). Blood 63: 1369–1371Google Scholar
  210. Köhler M, Hellstern P, Reiter B et al. (1984a) Behandlung des von Willebrand Jürgens Syndroms mit „hepatitissicheren“Faktor VIII-Konzentraten. Dtsch Med Wochenschr 109: 1800–1805PubMedGoogle Scholar
  211. Köhler M, Hellstern P, Reiter B et al. (1984b) The subcutaneous administration of the Vasopressin analogue l-Desamino-D-Arginine Vasopressin in patients with von Willebrand’s disease and hemophilia. Klin Wochenschr 62: 543–548PubMedGoogle Scholar
  212. Korninger Ch, Niessner H (1979) Systemische Therapie des von Willebrand Jürgens Syndroms mit Plasmaderivaten. In: Landbeck G, Marx R, Stolte HP (Hrsg) 10. Haemophilie-Symposion, Hamburg 1979. Pharmazeutische Verlagsgesellschaft, S 93–108Google Scholar
  213. Korninger Ch, Niessner H, Thaler E, Lechner K (1980) Wirkung von DDAVP auf Fibrinolyse-und Gerinnungsparameter. Untersuchung an Normalpersonen, Haemophilen und Patienten mit von Willebrand Jürgens Syndrom. In: Sutor AH (ed) DDAVP in bleeding disorders (1st Int Symposium on DDAVP in Bleeding Disorders, Münster 1979 ). Schattauer, Stuttgart New York, pp 55–6Google Scholar
  214. Korninger Ch, Niessner H, Lechner K (1981) Impaired fibrinolytic response to DDAVP and venous occlusion in a sub-group of patients with von Willebrand’s disease. Thromb Res 23: 365–374PubMedGoogle Scholar
  215. Koutts J, Lavergne JM, Meyer D (1977) Immunological evidence that human factor VIII is composed of two linked moieties. Br J Haematol 37: 415–428PubMedGoogle Scholar
  216. Koutts J, Walsh PN, Plow EF et al. (1978) Active release of human platelet factor VHI-related antigen by adenosine diphosphate, collagen and thrombin. J Clin Invest 62: 1255–1263PubMedGoogle Scholar
  217. Koutts J, Howard MA, Firkin BG (1979) Factor VIII physiology and pathology in man. In: Brown EB (ed) Progress in hematology. Grune and Stratton, New York, pp 115–146Google Scholar
  218. Krishnamurthy M, Miotti AB (1977) Von Willebrand’s disease and pregnancy. Obstet Gynecol 49: 244PubMedGoogle Scholar
  219. Krizek DM, Rick ME, Williams SB, Gralnick HR (1983) Cryoprecipitate transfusion in variant von Willebrand’s disease and thrombocytopenia. Ann Intern Med 98: 484PubMedGoogle Scholar
  220. Kröniger A, Kumpe A, Wormsbächer W, Herchenhahn B (1982) Faktor-VIII-Konzentrate. Med Welt 33: 1027PubMedGoogle Scholar
  221. Kudo Y, Yokoyama M, Kimura A, Takamatsu H (1977) A case of combined deficiency of factor IX and factor VIII with prolonged bleeding time. Jap J Clin Hematol 18: 81Google Scholar
  222. Larrieu MJ, Soulier JP (1953) Deficit en facteur antihemophilique A chez une fille associe a un trouble du saignement. Rev Hematol 8: 361–37PubMedGoogle Scholar
  223. Larrieu MJ, Caen JP, Meyer D et al. (1968) Congenital bleeding disorders with long bleeding time and normal platelet count. II. von Willebrand’s disease (report of 37 patients). Am J Med 45: 354 — 372PubMedGoogle Scholar
  224. Laurell CB (1965) Antigen-antibody crossed electrophoresis. Anal Biochem 10: 358PubMedGoogle Scholar
  225. Laurell CB (1966) Quantitative estimation of protein by electrophoresis in agarose gel containing antibodies. Anal Biochem 15: 45PubMedGoogle Scholar
  226. Lazarchick J, Hoyer LW (1978) Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 62: 1048–1052PubMedGoogle Scholar
  227. Lechner K (1982) Blutgerinnungsstörungen-Laboratoriumsdiagnose hämatologischer Erkrankungen. Springer, Berlin Heidelberg New YorkGoogle Scholar
  228. Lechner K, Niessner H, Stych H (1975) Zur Vermeidung postoperativer Blutungszwischenfälle bei Operationen im Hals-, Nasen-, Ohrenbereich. Österr Ärztezeitung 30: 1310Google Scholar
  229. Legaz ME, Schmer G, Counts RB, Davie EW (1973) Isolation and characterization of human factor VIII (antihemophilic factor). J Biol Chem 248: 3946–3955PubMedGoogle Scholar
  230. Legrand YJ, Rodriguez-Zeballos A, Kartalis G et al. (1978) Adsorption of factor VIII antigen-activity complex by collagen. Thromb Res 13: 909PubMedGoogle Scholar
  231. Lehmann W (1959) Neuere Untersuchungen zur Thrombopathie (von Willebrand-Jürgens) auf den Älands-Inseln (Finnland). Acta Genet Med [Suppl] 2: 68Google Scholar
  232. Leone G, Pola P, Guerra G et al. (1974) Sindrome di von Willebrand acquisita in corso di malattia disreattiva. Haematologica 59: 212PubMedGoogle Scholar
  233. Leone G, Moneta E, Paparotti G, Boni P (1975) von Willebrand’s disease in pregnancy. N Engl J Med 293: 456Google Scholar
  234. Leupin L, Beck EA, Furlan M, Bucher U (1983) Hämostasestörung mit verminderter Aktivität des von Willebrand-Faktors bei myeloproliferativen Syndromen. Schweiz Med Wochenschr 113: 713–71PubMedGoogle Scholar
  235. Lian ECY, Deykin D (1976) Diagnosis of von Willebrand’s disease. A comparative study of diagnostic tests on nine families with von Willebrand’s disease and its differential diagnosis from hemophilia and thrombocytopathy. Am J Med 60: 344–356Google Scholar
  236. Lopez Fernandez MF, Ginsberg MH, Ruggeri ZM (1982) Multimeric structure of platelet factor VIII/von Willebrand factor: The presence of larger multimers and their reassociation with thrombin stimulated platelets. Blood 60: 1132–1138Google Scholar
  237. Ludlam CA, Peake IR, Allen N et al. (1980) Faktor VIII and fibrinolytic response to deamino–d-arginine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand’s disease. Br J Haematol 45: 499–511PubMedGoogle Scholar
  238. Lynch DC, Williams R, Kirby E et al. (1982) Mechanism of factor VIIIR (von Willebrand factor) synthesis by bovine endothelial cells. Clin Res 30: 506aGoogle Scholar
  239. Lynch DC, Williams R, Zimmerman TS, Kirby E, Livingston DM (1983) Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells. Proc Natl Acad Sei USA 80: 2738Google Scholar
  240. MacFarlane DE, Stibbe J, Kirby EP et al. (1975) A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 34: 306–308PubMedGoogle Scholar
  241. Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical quantitation of antigens by simple radial immunodiffusion. Immunochemistry 2: 235PubMedGoogle Scholar
  242. Mannucci PM, Ruggeri ZM, Gagantelli G (1971) Nervous regulation of factor VIII levels in man. Br J Haematol 20: 195PubMedGoogle Scholar
  243. Mannucci PM, Pareti FI, Ruggeri ZM (1974) Enhanced factor VIII activity in von Willebrand’s disease. N Engl J Med 290: 1259PubMedGoogle Scholar
  244. Mannucci PM, Äberg M, Nilsson IM, Robertson B (1975) Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30: 81–93PubMedGoogle Scholar
  245. Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N, Lavergne JM (1976 a) Precipitating antibodies in von Willebrand’s disease. Nature 262: 141–142Google Scholar
  246. Mannucci PM, Pareti FI, Holmberg L et al. (1976b) Studies on the prolonged bleeding time in von Willebrand’s disease. J Lab Clin Med 88: 662–671PubMedGoogle Scholar
  247. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977a) l-deamino–8-d-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet 1: 869–872Google Scholar
  248. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977 b) DD A VP in haemophilia. Lancet II: 1171 (letter)Google Scholar
  249. Mannucci PM, Canciani MT, Rota L, Donovan BS (1981 a) Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 47: 283–293Google Scholar
  250. Mannucci PM, Ruggeri ZM, Ciavarella N (1981b) Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand’s disease: Effects on replacement therapy. Blood 57: 25–31Google Scholar
  251. Mannucci PM, Lombardi R, Pareti FI, Solinas S, Mazzucconi MG, Mariani G (1983) A variant of von Willebrand’s disease (vWd) characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers. Blood 62: 1000–1005PubMedGoogle Scholar
  252. Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM (1984) On behalf of the European thrombosis research organization (ETRO). Atherosclerosis and von Willebrand factor. 1. Prevalence of severe von Willebrand’s disease in Western Europe and Israel. Br J Hemat 57: 163–169Google Scholar
  253. Mant MJ, Hirsh J, Gauldie J et al. (1973) Von Willebrand’s syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammopathy. Blood 42: 429–436PubMedGoogle Scholar
  254. Maragall S, Ordinas A, Rodriguez M, Liendo F, Castillo R (1979) Inhibition to Willebrand factor in von Willebrand disease. Thromb Res 14: 495–501PubMedGoogle Scholar
  255. Marco L de, Shapiro SS (1981) Properties of human asialofactor VIII. A ristocetin-independent platelet-aggregating agent. J Clin Invest 68: 321–328Google Scholar
  256. Markwardt F (1983) Gefäßwand und Fibrinolyse. Arzneimittelforsch 33: 1370Google Scholar
  257. Marx R (1959) The problem of differentiating pseudohemophilias. In: Brinkhous KM, Nicola P de (eds) Hemophilia and other hemorrhagic states. University of North Carolina Press, Chapel Hill, pp 108–12Google Scholar
  258. Marx R, Jean G (1964) Zur Pathogenese der von Willebrand Jürgens Syndrome. Eine klinische und submikroskopische Studie. Klin Wochenschr 42: 491Google Scholar
  259. McCarroll DR, Ruggeri ZM, Montgomery RR (1984) The effect of DDAVP on plasma levels of von Willebrand antigen II in normal individuals and patients. Blood 63: 532–535PubMedGoogle Scholar
  260. McMichael AJ, Rust NA, Pilch JR, Sochynsky R, Morton J, Mason DY, Ruan C, Tobelem G, Caen J (1981) Monoclonal antibody to human platelet glycoprotein I. I. Immunological studies. Br J Haematol 49: 501Google Scholar
  261. Meili EQ, Straub PW, Frick PG (1969) Zur Pathogenese und Behandlung der von Willebrand’schen Krankheit. Schweiz Med Wochenschr 99: 1805PubMedGoogle Scholar
  262. Meyer D, Baumgartner HR (1983) Role of von Willebrand factor in platelet adhesion to the subendothelium. Br J Haematol 54: 1–9PubMedGoogle Scholar
  263. Meyer D, Lavergne JM, Larrieu MJ, Josso F (1972) Crossreacting material in congenital factor VIII deficiences ( Hemophilia A and von Willebrand’s disease ). Thromb Res 1: 183–195Google Scholar
  264. Meyer D, Jenkins CSP, Dreyfus MD (1974) Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Br J Haematol 28: 579Google Scholar
  265. Meyer D, Frommel D, Larrieu MJ, Zimmerman TS (1979) Selective absence of large forms of factor VIII/von Willebrand factor in acquired von Willebrand’s syndrome. Response to transfu-sion. Blood 54: 600–60Google Scholar
  266. Meyer D, Obert B, Pietu G et al. (1980) Multimeric structure of factor VIII/von Willebrand factor in von Willebrand’s disease. J Lab Clin Med 95: 590–602PubMedGoogle Scholar
  267. Meyer D, Baumgartner HR, Edgington TS (1981) Effect of hybridoma antibodies to human factor VIII/von Willebrand factor on the adhesion of platelets to the subendothelium. Blood 58: 237a (abstract)Google Scholar
  268. Meyer D, Lavergne JM, Baumgartner HR, Tobelem G, Pietu G, Edgington TS (1983) Monoclonal antibodies to human von Willebrand factor: Role of intramolecular loci in mediation of platelet adhesion to the subendothelium. Thromb Haemostas 50: 191 (abstract)Google Scholar
  269. Mielke CH, Kaneshiro MM, Mäher IA et al. (1969) The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34: 204–215PubMedGoogle Scholar
  270. Miller CH, Graham JG, Goldin LR, Elston RC ( 1979 a) Genetics of classic von Willebrand’s disease. I. Phenotypic variation within families. Blood 54: 117Google Scholar
  271. Miller CH, Graham JB, Goldin LR, Elston RC ( 1979 b) Genetics of classic von Willebrand’s disease. II. Optimal assignment of the heterozygous genotype (diagnosis) by discriminant analysis. Blood 54: 137Google Scholar
  272. Miller JL, Castella A (1982) Platelet-type von Willebrand’s disease: Characterization of a new bleeding disorder. Blood 60: 790–794Google Scholar
  273. Miller JL, Kupinsi JM, Castella A, Ruggeri ZM (1983) Von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. J Clin Invest 72: 1532–154PubMedGoogle Scholar
  274. Minot GR (1928) A familial hemorrhagic condition associated with prolongation of the bleeding time. Am J Med Sei 175: 301Google Scholar
  275. Miyashita C, Hellstern P, Köhler M et al. (1984) In vitro characterization of commercial factor VIII concentrates longterm follow-up. Blut 48: 1–7Google Scholar
  276. Moake JL, Olson JD, Troll JH, Tang SS, Funicella T, Peterson DM (1980) Binding of radioiodinated human von Willebrand factor to Bernard-Soulier Syndrom, thrombasthenic and von Willebrand platelets. Thromb Res 19: 21PubMedGoogle Scholar
  277. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin DL (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307: 1432–1435PubMedGoogle Scholar
  278. Montgomery RR, Zimmerman TS (1978) von Willbrand’s disease antigen II (vW:Ag II). A new plasma and platelet antigen deficient in severe von Willebrand’s disease. J Clin Invest 61: 1498–150Google Scholar
  279. Montgomery RR, Zimmerman TS (1978) von Willbrand’s disease antigen II (vW:Ag II). A new plasma and platelet antigen deficient in severe von Willebrand’s disease. J Clin Invest 61: 1498–150Google Scholar
  280. Morisato DK, Gralnick HR (1980) Selective binding of the factor VIII/von Willebrand factor protein to human platelets. Blood 55: 9–15PubMedGoogle Scholar
  281. Mourik JA van, Bouma BN, Bruyere WT la et al. (1974) Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res 4: 155–164PubMedGoogle Scholar
  282. Müntz RH, Ekert M, Helliger H (1974) Properties of postinfusion factor VIII in von Willebrand’s disease. Thromb Res 5: 111PubMedGoogle Scholar
  283. Nachman RL, Jaffe EA (1975) Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med 141: 1101–1113PubMedGoogle Scholar
  284. Nachman R, Levine R, Jaffe EA (1977) Synthesis of factor VHI-antigen by cultured guineapig megakaryocytes. J Clin Invest 60: 914–921PubMedGoogle Scholar
  285. Nielsen EG, Svejgard A (1967) von Willebrand’s disease associated with intermittent thrombocytopenia. Lancet II: 966Google Scholar
  286. Niessner H (1972) Messung der Plättchenadhäsivität mit einer modifizierten Form der Hellem Ii-Methodik unter besonderer Berücksichtigung des von Willebrand-Jürgens-Syndrom. Thromb Diath Hämorrh 27: 434Google Scholar
  287. Niessner H (1976) Die Laboratoriumsdiagnostik des von Willebrand-Jürgens-Syndroms. Wien Klin Wochenschr 88: 221–23PubMedGoogle Scholar
  288. Niessner H (1977) Two cases of acquired von Willebrand’s syndrome with associated monoclonal gammopathy. In: Workshop on Inhibitors of Factors VIII and IX, Jan 26th and 27th, 1976, Facultas, Wien, p 185Google Scholar
  289. Niessner H (1978) Das analytische Spektrum zur Diagnostik des von Willebrand Jürgens Syndroms. In: Heene DL (Hrsg) Immunologische Probleme der Blutgerinnung, von Willebrand Jürgens Syndrom. Verhandlungsbericht der Dtsch Arbeitsgemeinschaft für Blutgerinnungsforschung Giessen 1976. Schattauer, Stuttgart New York, S 199Google Scholar
  290. Niessner H (1981) Das erworbene von Willebrand Jürgens Syndrom. In: Scharrer J, Breddin K (Hrsg) Haemostase und Atherosklerose bei Haemophilie und von Willebrand-Syndrom. ( 14. Angiologisches Symposium in Kitzbühel.) Schattauer, Stuttgart, New York, S 39Google Scholar
  291. Niessner H (1982) Neue Erkenntnisse beim von Willebrand Jürgens Syndrom. Acta Med Austriaca [Suppl] 2: 44 — 50Google Scholar
  292. Niessner H (1983) Die Rolle von Faktor VIII bei der Interaktion von Plättchen und Gefäßendothel. Arzneimittelforsch 33: 1379–1383Google Scholar
  293. Niessner H, Brenner B (1982) Zur Methodik der Bestimmung des Ristocetin-Cofaktors. In: Landbeck G, Marx R, Stolte HP (Hrsg), 11. Haemophilie Symp Hamburg 1980. Pharmazeutische Verlags-Gesellschaft, München, S 91–105Google Scholar
  294. Niessner H, Korninger CH (1983) DD A VP-an alternative in the management of mild hemophilia A and von Willebrand’s disease. Wien Klin Wochenschr 95: 753–757PubMedGoogle Scholar
  295. Niessner H, Lechner K (1979) Failure of cryoprecipitate to normalize platelet retention in heriditary and acquired von Willebrand’ disease. Thromb Haemostas 42: 442 (abstract)Google Scholar
  296. Niessner H, Korninger CH, Lechner K (1981) Impaired fibrinolytic response to DDAVP and venous occlusion in a subgroup of patients with von Willebrand’s disease. Thromb Haemostas 46: 123 (abstract)Google Scholar
  297. Nieuwenhuis HK, Sixma JJ (1983) Bleeding time measurements. In: Harker LA, Zimmerman ThS (eds) Measurements of platelet function, methods in hematology, vol 8. Churchill Livingstone, Edinburgh London Melbourne New York, pp 26–45Google Scholar
  298. Nilsson IM (1977) Von Willebrand’s disease-fifty years old. Acta Med Scand 201: 497PubMedGoogle Scholar
  299. Nilsson IM (1978) Report of working party on factor VHI-related antigens. Thromb Haemostas 39: 511–52Google Scholar
  300. Nilsson IM, Blomback M (1963) Von Willebrand’s disease in Sweden. Occurence, pathogenesis and treatment. Thromb Diath Haemorrh [Suppl 2] 9: 103Google Scholar
  301. Nilsson IM, Hedner U (1977) Characteristics of various factor VIII concentrates used in treatment of haemophilia A. Br J Haematol 37: 543–557PubMedGoogle Scholar
  302. Nilsson IM, Holmberg L (1979) Von Willebrand’s disease today. Clin Haematol 8: 147PubMedGoogle Scholar
  303. Nilsson IM, Robertson B (1968) Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects. Thromb Diath Haemorrh 20: 397–408PubMedGoogle Scholar
  304. Nilsson IM, Blomback M, Francken I von ( 1957 a) On an inherited autosomal hemorrhagic’ diathesis with antihemophilic globulin ( AHG) deficiency and prolonged bleeding time. Acta Med Scand 159: 35–5Google Scholar
  305. Nilsson IM, Blomback M, Jorpes E et al. (1957b) Von Willebrand’s disease and its correction with human fraction I-O. Acta Med Scand 159: 179–188PubMedGoogle Scholar
  306. Nilsson IM, Blomback M, Blomback B (1959) Von Willebrand’s disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 164: 263–278Google Scholar
  307. Nilsson IM, Magnusson S, Borchgrevink KC (1963) The Duke and Ivy methods for determination of the bleeding time. Thromb Diath Haemorrh 10: 223–234PubMedGoogle Scholar
  308. Nilsson IM, Bergentz SE, Larsson SA (1979 a) Surgery in von Willebrand’ disease. Ann Surg 190: 746Google Scholar
  309. Nilsson IM, Walter H, Mikaelson M, Vilhardt H (1979b) Factor VIII concentrate prepared form DDAVP stimulated blood donor plasma. Scand J Haematol 22: 42PubMedGoogle Scholar
  310. Nilsson IM, Holmberg L, Aberg M, Vilhardt H (1980a) The release of plasminogen activator and factor VIII after injection of DD AVP in healthy volunteers and in patients with von Willebrand’s disease. Scand J Haematol 24: 351Google Scholar
  311. Nilsson IM, Peake IR, Bloom AL, Meyer D, Veitkamp JJ, Green D (1980b) Report of the working party on factor VIII related antigen. Addendum: The relationship between ristocetin cofactor activity (VIII: RiCof) and factor VIII related antigen ( VIIIR: Ag) Thromb Haemostas 43: 167–168Google Scholar
  312. Nilsson IM, Vilhardt H, Holmberg L, Ästedt B (1982) Association between factor VIII related antigen and plasminogen activator. Acta Med Scand 211: 105–112PubMedGoogle Scholar
  313. Noller KL, Bowie EJW, Kempers RD (1973) von Willebrand’s disease in pregnancy. Obstet Gynecol 41: 865Google Scholar
  314. Nyman D (1977) Interaction of collagen with the factor VIII antigenactivity von Willebrand factor complex. Thromb Res 11: 433PubMedGoogle Scholar
  315. Nyman D (1980) von Willebrand factor dependent platelet aggregation and adsorption of factor VHI-related antigen by collagen. Thromb Res 17:209Google Scholar
  316. Nyman D, Eriksson AW, Blombäck M, Fronts RR, Wahlberg P (1981) Recent investigations of the first bleeder family in Aland (Finland) described by von Willebrand. Thromb Haemostas 45 /1: 73–7Google Scholar
  317. Ockelford PA, Chandrasekhara Menon N, Berry EW (1980) Clinical experience with arginine vasopressin ( DDAVP) in von Willebrand’s disease and mild haemophilia. New Zealand Med J 92: 375–37Google Scholar
  318. Ogata K, Saito H, Ratnoff OD (1983) The relationship of the properties of antihemophilic factor (factor VIII) that support ristocetin-induced platelet agglutination (factor VIIIR: RC) and platelet retention by glass beads as demonstrated by a monoclonal antibody. Blood 61: 27–35Google Scholar
  319. Olson JD, Brockway WJ, Fass DN et al. (1977) Purification of porcine and human ristocetin Willebrand factor. J Lab Clin Med 89: 1278–1294PubMedGoogle Scholar
  320. Over J, Vlooswijk HAA, Sixma JJ (1977) Assay of F VHI-related antigen in a variant of von Willebrand’s disease. Thromb Haemostas 37: 367–370Google Scholar
  321. Over J, Bouma BN, Mourik JA van (1978) Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med 91: 32–46Google Scholar
  322. Over J, Sixma JJ, Bouma BN et al. (1981) Survival of iodine–12-labeled factor VIII in patients with von Willebrand’s disease. J Lab Clin Med 97: 332–344PubMedGoogle Scholar
  323. Owen CA Jr, Bowie EJW, Zollman PE (1974) Carriers of porcine von Willebrand’s disease. Am J Vet Res 35: 245–24PubMedGoogle Scholar
  324. Owen CA, Bowie EJW, Fass DN, Perez RA, Cole TL, Stewart M (1979) Hypofibrinogenemia-dysfibrinogenemia and von Willebrand’s disease in the same family. Mayo Clin Proc 54: 375PubMedGoogle Scholar
  325. Owen WG, Wagner RH (1972) Antihemophilic factor: Separation of an active fragment following dissociation by salts or detergents. Thromb Diath Haemorrh 27: 502–515Google Scholar
  326. Paulssen MMP, Graaf-Wildschut M van de, Kolhorn A, Planje MC (1975) Radioimmunoassay of antihaemophilic factor (factor VIII) antigen. Clin Chim Acta 63: 349–353PubMedGoogle Scholar
  327. Peake IR (1982) Immunoradiometric assays of factor VIII. In: Bloom AL (ed) The Hemophilias, Methods in Hematology 5: 92–105Google Scholar
  328. Peake IR, Bloom AL ( 1977 a) Abnormal factor VIII related antigen (FVIIIRAG) in von Willebrand’s disease (vWd): Decreased precipitation by concanavalin A. Thromb Haemostas 37: 361–362Google Scholar
  329. Peake IR, Bloom AL (1977 b) The use of an immunoradiometric assay for factor VHI-related antigen in the study of atypical von Willebrand’s disease. Thrombos Res 10: 27–32Google Scholar
  330. Peake IR, Bloom AL (1978) Immunoradiometric assay of procoagulant factor VHI-antigen in plasma and serum and its reduction in hemophilia-Preliminary studies on adult and fetal blood. Lancet 1: 473–47PubMedGoogle Scholar
  331. Peake IR, Bloom AL, Giddings JC (1974) Inherited variants of factor VHI-related protein in von Willebrand’s disease. N Engl J Med 291: 113–117PubMedGoogle Scholar
  332. Perkins HA (1967) Correction of the hemostatic defect in von Willebrand’s disease. Blood 30: 375–380PubMedGoogle Scholar
  333. Perret BA, Furlan M, Beck EA (1979) Studies in factor VHI-related protein. II. Estimation of molecular size differences between factor VIII oligomers. Biochim Biophys Acta 578: 164–174Google Scholar
  334. Pickering NJ, Brody JI, Barrett MJ (1981) Von Willebrand syndromes and mitral-valve prolapse. N Engl J Med 305: 131PubMedGoogle Scholar
  335. Piovella F, Nalli G, Malamani GD et al. (1978) Ultrastructural localization of factor VHI-antigen in human platelets, megakaryocytes and endothelial cells utilizing a ferritin-labelled antibody. Br J Haematol 39: 209–213PubMedGoogle Scholar
  336. Pool JG, Shannon AE (1965) Production of high-potency concentrates of antihemophilic globulin in a closedbag system: Assay in vitro and in vivo. N Engl J Med 273: 1443Google Scholar
  337. Pool-Wilson PA (1972) Acquired von Willebrand’s syndrome and systemic lupus erythematosus. ProcRSoc Med 65: 561Google Scholar
  338. Potter EV, Chediak J, Green D (1976) Absence of ristocetin aggregation factor from the skin of a patient with von Willebrand’s disease. Lancet 1: 514PubMedGoogle Scholar
  339. Praga C, Valentini L, Maiorano M, Cortellaro M (1974) A new automatic device for the standardized Ivy bleeding time. In: Mannucci PM (ed) Platelet function and thrombosis: A review of methods. Plenum Press, New YorkGoogle Scholar
  340. Prowse CV, Sas G, Gader AM A, Cort JH, Cash JD (1979) Specifity in the factor VIII response to vasopressin infusion in man. Br J Haematol 41: 437–447PubMedGoogle Scholar
  341. Quick A J (1967) Teleangiectasia: its relationship to the Minot-von Willebrand syndrome. Am J Med Sci 254: 585PubMedGoogle Scholar
  342. Quick AJ, Adlam RT (1963) Coexistence of von Willebrand’s disease and hemophilia in a family. JAMA 185: 635PubMedGoogle Scholar
  343. Quick AJ, Hussey CV (1953) Hemophilic condition in the female. J Lab Clin Med 42: 929Google Scholar
  344. Ramsay DM, Macleod DAD, Buist TAS, Heading RC (1976) Persistent gastrointestinal bleeding due to angiodysplasia of the gut in von Willebrand’s disease. Lancet II: 275Google Scholar
  345. Ramsey R, Evatt BL (1979) Rapid assay for von Willebrand factor activity using formalin-fixed platelets and microtitration technic. Am J Clin Pathol 72: 996PubMedGoogle Scholar
  346. Rand JH, Gordon RE, Sussman II (1980 a) Electron microscopic localization of factor VIII-related antigen in human blood vessels. Circulation 62: 111–169Google Scholar
  347. Rand HJ, Sussman II, Gordon RE, Chu SV, Solomon V (1980 b) Localization of factor-VHI-related antigen in human vascular subendothelium. Blood 55: 752Google Scholar
  348. Ratnoff OD (1978) Antihemophilic factor (factor VIII). Ann Intern Med 88: 403–409PubMedGoogle Scholar
  349. Ratnoff OD, Bennett B (1973) Clues to pathogenesis of bleeding in von Willebrand’s disease. N Engl J Med 289: 1182–1183PubMedGoogle Scholar
  350. Ratnoff OD, Saito H (1974) Bleeding in von Willebrand’s disease. N Engl J Med 290: 1089PubMedGoogle Scholar
  351. Ratnoff OD, Slover CC, Poon MC (1976) Immunologic evidence that the properties of human antihemophilic factor (factor VIII) are attributes of a single molecular species. Blood 47: 657–667PubMedGoogle Scholar
  352. Read MS, Shermer RW, Brinkhous KM (1978) Venom coagglutinin: An activator of platelet aggregation dependent on von Willebrand factor. Proc Natl Acad Sci USA 75: 4514–451Google Scholar
  353. Reddick RL, Griggs TR, Lamb MA, Brinkhous KM (1982) Platelet adhesion to damaged arteries. Comparison in normal and von Willebrand disease swine. Proc Natl Acad Sci USA 79: 5076Google Scholar
  354. Reisner HM, Katz HJ, Goldin LR et al. (1978) Use of a simple visual assay of Willebrand factor for diagnosis and carrier identification. Br J Haematol 40: 339–350PubMedGoogle Scholar
  355. Reisner HM, Barrow ES, Graham JB (1979) Radioimmunoassay for coagulant factor VHI-related antigen ( VIIIC: Ag). Thromb Res 14: 235–239Google Scholar
  356. Report of a WHO Scientific group (1972) Inherited blood clotting disorders. WHO technical report 504. Geneva, WHOGoogle Scholar
  357. Rivard GE, Daviault MB (1978) A simplified assay for von Willebrand factor. Thromb Res 12: 677PubMedGoogle Scholar
  358. Rivard GE, Daviault MB, Brault N, D’Aragon L, Raymond R (1977) von Willebrand’s disease associated with thrombocytopenia and a fast migrating factor VIII related antigen. Thromb Res 11: 507Google Scholar
  359. Rizza CR (1961) Effect of exercise on the level of antihemophilic factor in the human blood. J Physiol 156: 128PubMedGoogle Scholar
  360. Rosborough TK, Swaim WR (1978) Acquired von Willebrand’s disease, platelet-release defect and angiodysplasia. Am J Med 65: 96–100PubMedGoogle Scholar
  361. Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis. N Engl J Med 295: 369–377PubMedGoogle Scholar
  362. Roussi JH, Houbouyan LL, Alterescu R, Franc B, Goguel AF (1980) Acquired von Willebrand’s syndrome associated with hairy cell leukaemia. Br J Haematol 46: 503–506PubMedGoogle Scholar
  363. Ruan C, Tobelem G, McMichael AJ, Drouet L, Legrand Y, Degos L, Kieffer N, Lee H, Caen JP (1981) Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function. Br J Haematol 49: 511Google Scholar
  364. Rubin H, Alter AA, Walker MR, Stefanyshyn M, Scott L, Miotti AB (1976) Evidence that the platelet retention factor is separate from the factor VHI-related antigen and factor VIII. J Lab Clin Med 88: 14PubMedGoogle Scholar
  365. Ruggeri ZM, Zimmerman TS (1980) Variant von Willebrand’s disease: Characterization of two subtypes by analysis of multimeric composition of factor Vlll/von Willebrand factor in plasma and platelets. J Clin Invest 65: 1318–1325Google Scholar
  366. Ruggeri ZM, Zimmerman TS (1981) The complex multimeric composition of factor Vlll/von Willebrand factor. Blood 57: 1140–1143PubMedGoogle Scholar
  367. Ruggeri ZM, Pareti FI, Bintadis P, Mannucci PM (1974) Clotting factors in von Willebrand’s disease. Lancet 11: 105–10Google Scholar
  368. Ruggeri ZM, Mannucci PM, Jeffcoate SL, Ingram GIC (1976) Immunoradiometric assay of factor VHI-related antigen. With observations in 32 patients with von Willebrand’s disease. Br J Haematol 33: 221–23PubMedGoogle Scholar
  369. Ruggeri ZM, Mannucci PM, Bader R, Barbui T (1978) Factor VHI-related properties in platelets from patients with von Willebrand’s disease. J Lab Clin Med 91: 132–140PubMedGoogle Scholar
  370. Ruggeri ZM, Ciavarella N, Mannucci PM (1979) Familian incidence of precipitating antibodies in von Willebrand’s disease. A study of four cases. J Lab Clin Med 94: 60–75Google Scholar
  371. Ruggeri ZM, Pareti FI, Mannucci PM et al. (1980) Heightened interaction between platelets and factor Vlll/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 302: 1047–105PubMedGoogle Scholar
  372. Ruggeri ZM, Bader R, Coppola R et al. (1981) The multimeric structure of factor Vlll/von Wille-brand factor influences binding to a specific thrombin-induced receptor on the platelet surface. Blood [Suppl 1] 58: 204aGoogle Scholar
  373. Ruggeri ZM, Bader R, Marco L de (1982a) Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci USA 79: 6038–6041PubMedGoogle Scholar
  374. Ruggeri ZM, Lombardi R, Gatti L et al. (1982b) Type IIB von Willebrand’s disease: differential clearance of endogenous versus transfused large multimer von Willebrand factor. Blood 60: 1453PubMedGoogle Scholar
  375. Ruggeri ZM, Mannucci PM, Federici AB ( 1982 c) Multimeric composition of factor Vlll/von Willebrand factor following administration of DDAVP: Implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood 59: 1272–1278Google Scholar
  376. Ruggeri ZM, Nilsson IM, Lombardi R et al. (1982d) Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand’s disease (type IIC). J Clin Invest 70: 1124–1127PubMedGoogle Scholar
  377. Ruggeri ZM, De Marco L, Gatti L et al. (1983) Platelets have more than one binding site for von Willebrand factor. J Clin Invest 72: 1–12PubMedGoogle Scholar
  378. Sakariassen KS, Bolhuis PA, Sixma J J (1979) Human blood platelet adhesion to artery subendothelium is mediated by factor VIII/von Willebrand factor bound to the subendothelium. Nature 279: 636–63PubMedGoogle Scholar
  379. Sakariassen KS, Ottenhof-Rovers M, Sixma JJ (1984) Factor VIII-von Willebrand factor requires calcium for facilitation of platelets adherence. Blood 63: 996–1003PubMedGoogle Scholar
  380. Salzman EW (1963) Measurement of platelet adhesiveness: a simple in vitro technique demonstrating an abnormality in von Willebrand’s disease. J Lab Clin Med 62: 724–735PubMedGoogle Scholar
  381. Santoro SA (1981) Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 21: 689PubMedGoogle Scholar
  382. Santoro SA (1983) Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen. Biochem Biophys Acta 756: 123PubMedGoogle Scholar
  383. Sarji KE, Stratton RD, Wagner RH, Brinkhous KM (1974) Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc Natl Acad Sei USA 71: 2937Google Scholar
  384. Savidge GF, Carlebjörk G (1979) An optimised radioimmunoassay of F-VIII-related antigen ( FVIII-RAg) in plasma and eluates. Thromb Res 15: 363–376Google Scholar
  385. Scharrer I (1979) Bedeutung des Ristocetin-Cofaktors und der Ristocetin-induzierten Plättchenaggre-gation. In: Landbeck G, Marx R, Stolte HP (Hrsg) 10. Haemophilie Symp. Hamburg 1979. Pharmazeutische Verlagsgesellschaft, München, S 57–89Google Scholar
  386. Scharrer I (1980) Treatment of von Willebrand’s disease. In: Mammen EF, Barnhart MI, Lusher JM, Walsh RT (eds) Treatment of bleeding disorders. PID Publications Limited, Westbury/NY 11590,p 101Google Scholar
  387. Scharrer I (1981) Klinische Anwendung des DDAVP bei zahnärztlichen Eingriffen. In: Sutor AH (ed) Vasopressin Analogues and Haemostasis (2nd Intern Sympos on DDAVP and Glycylpressin in bleeding disorders, Münster 1980 ) Schattauer, Stuttgart New York, p 14Google Scholar
  388. Scherer HE, Niehues B, Lechler E (1982) Mitralklappenprolaps bei von Willebrand-Jürgens-Syndrom. In: Loo J van de, Asbeck F (Hrsg) Hämostase, Thrombophilie und Arteriosklerose. (Berichtband 2. Kongreß für Thrombose und Hämostase, Münster 1982). Schattauer, Stuttgart New York, S 511Google Scholar
  389. Schimpf K, Rothmann P (1980) Behandlung mit DDAVP während 18 Zahnextraktionen, 2 Muskel-blutungen, 1 Bisswunde und einer Kieferhöhlenspülung bei insgesamt 8 Patienten mit milder Haemophilie A. In: Sutor AH (ed) DDAVP in bleeding disorders (1st Int. Sympos. on DDAVP in bleeding disorders, Münster 1979 ). Schattauer, Stuttgart New YorkGoogle Scholar
  390. Schmitz-Huebner U, Balleisen L, Arends P, Pollmann H, Sutor AH (1980) DDAVP-induced changes of factor Vlll-related activities and bleeding time in patients with von Willebrand’s syndrome. Haemostasis 9: 204PubMedGoogle Scholar
  391. Schneider-Trip MD, Jenkins CSP, Kahle LH (1979) Studies on the mechanism of ristocetin-induced platelet aggregation: Binding of factor VIII to platelets. Br J Haematol 43: 99Google Scholar
  392. Scott JP, Montgomery RR (1981) Platelet von Willebrand’s antigen II: active release by aggregating agents and a marker of platelet release reaction in vivo. Blood 58: 1075–1080PubMedGoogle Scholar
  393. Scott JP, Montgomery RR, Tubergen DG, Hays T (1981) Acquired von Willebrand’s disease in association with Wilm’s tumor: Regression following treatment. Blood 58: 665–669Google Scholar
  394. Shapiro GA, Anderson JC, Pizzo SV, McKee PA (1973) The subunit structure of normal and hemophilic factor VIII. J Clin Invest 52: 2198–2210PubMedGoogle Scholar
  395. Shoai I, Lavergne JM, Ardaillou N et al. (1977) Heterogeneity of von Willebrand’s disease. Study of 40 Iranian cases. Br J Haematol 37: 67–83Google Scholar
  396. Silwer J (1973) von Willebrand’s disease in Sweden. Acta Paediatr Scand [Suppl] 238 Silwer N, Cronberg JS, Nilsson IM (1966) Occurrence of ateriosklerosis in von Willebrand’s disease. Acta Med Scand 180: 475–484Google Scholar
  397. Simone JV, Cornet JA, Abildgaard CF (1968) Acquired von Willebrand’s syndrome in systemic lupus erythematosis. Blood 31: 806–812PubMedGoogle Scholar
  398. Sixma JJ, Kater L, Bouma BN et al. (1976) Immunofluorescent localization of factor Vlll-related antigen, fibrinogen, and several other plasma proteins in hemostatic plugs in humans. J Lab Clin Med 87: 112–11PubMedGoogle Scholar
  399. Sixma JJ, Over J, Bouma BN, Bloom AL, Peake IR (1978) Predominance of normal low molecular weight forms or factor VIII in “variant” von Willebrand’s disease. Thromb Res 12: 929–936PubMedGoogle Scholar
  400. Sixma JJ, Sakariassen KS, Houdijk W, Aarts PAM (1983) Die Bedeutung der Plättchen-Gefäßwand-Reaktion in der Pathogenese der Atherosklerose. Arzneimittelforsch 33: 1355–1357Google Scholar
  401. Sixma JJ, Sakariassen KS, Beeser-Visser NH et al. (1984) Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 63: 128–13PubMedGoogle Scholar
  402. Slot JW, Bouma BN, Montgomery R, Zimmerman TS (1978) Platelet factor VIH-related antigen: Immunofluorescent localization. Thromb Res 13: 871–881Google Scholar
  403. Sodetz JM, Pizzo SV, McKee PA (1977) Relationship of sialicacid to function and in vivo survival of human factor VHI-von Willebrand factor protein. J Biol Chem 252: 5538–5546PubMedGoogle Scholar
  404. Sodetz JM, Paulson JC, Pizzo SV, McKee PA (1978) Carbohydrate on human factor VHI/von Willebrand factor. Impairment of function by removal of specific galactose residues. J Biol Chem 253: 7202–720Google Scholar
  405. Soff GA, Levin J (1981) Familial multiple coagulation factors deficiencies. I. Review of the literature: Differentiation of single hereditary disorders associated with multiple factor deficiencies from coincidental concurrence of single factor deficiency states. Semin Thromb Hemost VII /2: 112Google Scholar
  406. Solum NO, Hagen I, Peterka M, Gjemdal T (1979) Absence of the 145000 molecular weight, soluble platelet membrane glycoprotein-lack of agglutination. Thromb Haemostas 42: 1626Google Scholar
  407. Solum NO, Hagen I, Filion-Myklebust C, Staback T (1980) Platelet glycocalicin: Its membrane association and solubilization in aqueous media. Biochim Biophys Acta 597: 235Google Scholar
  408. Stableforth P, Tamagnini GL, Dormandy KM (1976) Acquired yon Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation. Br J Haematol 33: 565–57PubMedGoogle Scholar
  409. Stel HV, Sakariassen KS, Scholte BJ et al. (1984) Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood 63: 1408–1415PubMedGoogle Scholar
  410. Stibbe J (1977) Effect of exercise on FVIII-complex: proportional increase of ristocetin cofactor (von Willebrand factor) and FVIII-AGN, but disproportional increase of FVIII-AHF. Thromb Res 1: 163–16Google Scholar
  411. Stibbe J, Kirby EP (1976) The influence of haemaccel, fibrinogen and albumin on ristocetin-induced platelet aggregation. Relevance to the quantitative measurement of the ristocetin cofactor. Thromb Res 8: 151–16Google Scholar
  412. Stites DP, Hershgold EP, Perlman JD, Fudenberg HH (1971) Factor VIII detection by hemagglutination inhibition: Hemophilic A and von Willebrand’s disease. Science 171: 196–197Google Scholar
  413. Stratton RD, Wagner RH, Webster WP et al. (1975) Antibody nature of circulating inhibitor of plasma of von Willebrand factor. Proc Natl Acad Sci USA 72: 4167–4171PubMedGoogle Scholar
  414. Strauss HS, Bloom GE (1965) von Willebrand’s disease. Use of a platelet-adhesiveness test in diagnosis and family investigations. N Engl J Med 273: 171–181Google Scholar
  415. Strauss HS, Diamond LK (1963) Elevation of factor VIII (antihemophilic factor) during pregnancy in normal persons and in a patient with von Willebrand’s disease. N Engl J Med 269: 1251PubMedGoogle Scholar
  416. Stuart MJ, Miller ML, Davey FR, Walk JA (1979) The postaspirin bleeding time: a screening test for evaluating haemostatic disorders. Br J Haematol 43: 649–659PubMedGoogle Scholar
  417. Sultan Y (1981) Rationale for the treatment of von Willebrand’s disease. In Haemophilia and Haemostasis. Liss AR, Inc, New York, pp 149–162Google Scholar
  418. Sultan Y, Bernal-Hoyos EJ, Levy-Toledano S, Jeanneau C, Caen JP (1974) Dominant inherited familial factor VIII deficiency (von Willebrand disease) associated with thrombo-cytopathic thrombocytopenia (biologic and genetic implications). Pathol Biol 22: 27PubMedGoogle Scholar
  419. Sultan Y, Simeon J, Caen JP (1975) Detection of heterozygotes in both parents of homozygous patients with von Willebrand’s disease. J Clin Pathol 28: 309–316PubMedGoogle Scholar
  420. Sultan Y, Simeon J, Caen JP (1976) Electrophoretic heterogeneity of normal factor VHI/von Willebrand protein, and abnormal electrophoretic mobility in patients with von Willebrand’s disease. J Lab Clin Med 87: 185–197PubMedGoogle Scholar
  421. Sultan Y, Bouma BN, Graaf S de, Simeon J, Caen JP, Sixma JJ (1977) Factor VIII related antigen in platelets of patients with von Willebrand’s disease. Thromb Res 11: 23–30PubMedGoogle Scholar
  422. Sultan Y, Jeanneau C, Lamaziere J, Maisonneuve P, Caen JP (1978) Platelet factor VIH-related antigen: Studies in vivo after transfusion in patients with von Willebrand disease. Blood 51: 751–76Google Scholar
  423. Sultan Y, Maisonneuve P, Angeles-Cano E (1979) Release of VIIIR:Ag and VIIIR:WF during thrombin and collagen induced aggregation. Thromb Res 15: 415–425PubMedGoogle Scholar
  424. Sussman II, Weiss HJ (1978) Dissociation of factor VIII in the presence of proteolytic inhibitors. Thromb Haemostas 40: 316–32Google Scholar
  425. Sutor AH, Bowie EJW, Owen CA Jr (1971 a) A new method of demonstrating the effect of therapy in von Willebrand’s disease. Mayo Clin Proc 46: 345–346Google Scholar
  426. Sutor AH, Bowie EJW, Thompson JH, Didisheim P, Mertens BF, Owen CA (1971b) Bleeding from standardized skin punctures: automated technic for recording time, intersity and pattern of bleeding. Am J Clin Pathol 55: 541PubMedGoogle Scholar
  427. Sutor AH, Pollmann H, Arends P, Schmitz-Huebner U, Balleisen L (1980) DDAVP-induzierte Ver-änderungen der primären Haemostase bei Patienten mit von Willebrand-Jürgens-Syndrom. In: Sutor AH (ed) DDAVP in bleeding disorders (1st Intern Sympos on DDAVP in bleeding disorders Münster 1979 ). Schattauer, Stuttgart New York, p 85Google Scholar
  428. Switzer ME, McKee PA (1976) Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure. J Clin Invest 57: 925–937Google Scholar
  429. Takahashi H (1980) Studies on the pathophysiology and treatment of von Willebrand’s disease: IV. Mechanism of increased ristocetin-induced platelet aggregation in von Willebrand’s disease. Thromb Res 19: 857–86PubMedGoogle Scholar
  430. Takahashi H (1981) Studies on the pathophysiology and treatment of von Willebrand’s disease. V.Properties of factor VIII after DDAVP infusion in variant von Willebrand’s disease. Thromb Res 21: 357–36PubMedGoogle Scholar
  431. Takahashi H (1984) Type lib and platelet-type von Willebrand’s disease. Heightened interaction between von Willebrand factor and platelets. Blood Vessel 15: 111–127Google Scholar
  432. Takahashi H, Sakuragawa N, Shibata A (1980) von Willebrand disease with an increased ristocetin-induced platelet aggregation and a qualitative abnormality of the factor VIII protein. Am J Hematol 8: 299–30Google Scholar
  433. Taylor J (1968) von Willebrand’s disease in obstetrics and gynaecology. J Obstet Gynaecol Br Commonw 75:453Google Scholar
  434. Telfer MC, Chediak J (1977) Factor VHI-related disorders and their relationship to pregnancy. JReprod Med 19: 211Google Scholar
  435. Theiss W, Sauer E (1977) DDAVP: Alternative to replacement treatment in mild haemophilia A and von Willebrand-Jürgens syndrome. Dtsch Med Wochenschr 102: 1769–1772Google Scholar
  436. Theiss W, Schmidt G (1978) DDAVP in von Willebrand’s disease: repeated administration and the behaviour of the bleeding time. Thromb Res 13: 1119PubMedGoogle Scholar
  437. Thomson C, Forbes CD, Prentice CRM (1973) Relationship of factor VIII to ristocetin induced platelet aggregation. Effect of heterologous and acquired factor VIII antibodies. Thromb Res 3: 363Google Scholar
  438. Tilsner V, Reuter H (1982) Nebenwirkungen der Faktor Vlll-Substitution bei Patienten mit Hämophilie A. Münchner Med Wochenschr 124: 553Google Scholar
  439. Ts’ao CH, Green D, Schultz K (1976) Function and ultrastructure of platelets of neonates: enhanced ristocetin induced aggregation of neonatal platelets. Br J Haematol 32: 225–233PubMedGoogle Scholar
  440. Tschopp TB, Weiss HJ, Baumgartner HR (1974) Decreased adhesion of platelets to subendothelium in von Willebrand’s disease. J Lab Clin Med 83: 296–300PubMedGoogle Scholar
  441. Tschopp TB, Baumgartner HR, Silberbauer K, Sinzinger H (1979) Platelet adhesion and platelet thrombosis formation on subendothelium of human arteries and veins exposed to flowing blood in vitro. A comparison with rabbit aorta. Haemostasis 8: 19–29Google Scholar
  442. Tuddenham EGD, Trabold NC, Collins JA, Hoyer LW (1979) The properties of factor VIII coagulant activity prepared by immunoadsorbent chromatography. J Lab Clin Med 93: 40–53PubMedGoogle Scholar
  443. Tuddenham EGD, Lazarchick J, Hoyer LW (1981) Synthesis and release of factor VIII by cultured human endothelial cells. Br J Haematol 47: 617–626PubMedGoogle Scholar
  444. Tuddenham EGD, Lane RS, Rotblat F et al. (1982) Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand’s disease. Br J Haematol 52: 259–267PubMedGoogle Scholar
  445. Turitto VT, Baumgartner HR (1983) Platelet adhesion. In: Harker LA, Zimmerman ThS (eds) Measurements of platelet function, methods in hematology, vol 8. Churchill Livingstone, Edinburgh London Melbourne New York, pp 46–63Google Scholar
  446. Turitto V, Weiss H, Sussman I, Zimmerman T (1981) Factor VIII in vessel wall influences platelet interaction with subendothelium. Thromb Haemostas 46: 199Google Scholar
  447. Valente A, Volpe E, Gandini M, Buonanna G (1972) von Willebrand’s disease: platelet nucleotide alterations in a case with a marked platelet adhesiveness and aggregation defects. Acta Haematol 47: 182Google Scholar
  448. Vehar GA, Davie EW (1980) Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 19: 401–410PubMedGoogle Scholar
  449. Veitkamp JJ, Tilburg NH von (1973) Detection of heterozygotes for recessive von Willebrand’s disease by the assay of antihemophilic factor like antigen. N Engl J Med 289: 882–885Google Scholar
  450. Veltkamp JJ, Stevens P, Pias M van de et al. (1970) Production site of bleeding factor (acquired morbus von Willebrand). Thromb Diath Haemorrh 23: 412PubMedGoogle Scholar
  451. Vermylen J, Donati MD, Gaetano G de et al. (1973) Aggregation of human platelets by bovine or human factor VIII: role of carbohydrate side chains. Nature 244: 167–168PubMedGoogle Scholar
  452. Vermylen J, Gaetano G de, Donati MB et al. (1974) Platelet-aggregating activity in neuraminidase treated human cryoprezipitates: its correlation with factor VHI-related antigen. Br J Haematol 26: 645–65PubMedGoogle Scholar
  453. Vermylen J, Bottecchia D, Szpilman H (1976) Factor VIII and human platelet aggregation. III. Further studies on aggregation of human platelets by neuraminidase-treated human factor VIII. Br J Haematol 34: 321–330Google Scholar
  454. Vilhardt H, Äberg M, Nilsson IM (1980) Possible uses of DDAVP in coagulation disorders. In: Sutor AH (ed) DDAVP in bleeding disorders. (1st Intern Symposium on DDAVP in bleeding disorders, Münster 1979 ). Schattauer, Stuttgart New York, p 36Google Scholar
  455. Voss H von (1982) Bestimmungsmethoden des Faktor VIII:RCF. In: Landbeck G, Marx R, Stolte HP (Hrsg) 11. Haemophilie Symp Hamburg 1980. Pharmazeutische Verlagsgesellschaft, München, S 81–9Google Scholar
  456. Vukovich TH, Koller E, Doleschel W, Mayr WR (1980) Faktor VHI-Präparate unterschiedlicher Reinheit-Untersuchung physiko-chemischer Parameter. Wien Klin Wochenschr 92: 385PubMedGoogle Scholar
  457. Wagner DD, Marder VJ (1983) Biosynthesis of von Willebrand protein by human endothelial cells: Identification of a large precursor polypeptide chain. J Biol Chem 258: 2065Google Scholar
  458. Wahlberg TB, Blomback M, Ruggeri ZM (1983) Differences between heterozygous dominant and recessive von Willebrand’s disease type I expressed by bleeding symptoms and combinations of factor VIII variables. Thromb Haemostas 50: 864–868Google Scholar
  459. Walker EH, Dormandy KM (1968) The management of pregnancy in von Willebrand’s disease. J Obstet Gynaec Br Cwlth 75: 459Google Scholar
  460. Wall RT, Counts RB, Harker LA, Striker GE (1980) Binding and release of factor VIII/von Willebrand factor by human endothelial cells. Br J Haematol 46: 287–298PubMedGoogle Scholar
  461. Warner AI, Lusher JM (1983) DDAVP a useful alternative to blood components in moderate haemophilia A and in von Willebrand’s disease. J Pediatr 102: 228Google Scholar
  462. Wautier JL, Levy-Toledano S, Caen JP (1976) Acquired von Willebrand’s syndrome and thrombopathy in a patient with chronic lymphocytic leukemia. Scand J Haematol 16: 128PubMedGoogle Scholar
  463. Weinger RS, Cimo PL, Moake JL (1981) Type IIB von Willebrand’s disease: Unusual response to cryoprecipitate infusion. Ann Intern Med 94: 47–50Google Scholar
  464. Weinstein M, Deykin D (1979) Comparison of factor VHI-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate. Blood 53: 1095–1105PubMedGoogle Scholar
  465. Weinstein M, Chute L, Deykin D (1981) Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma. Proc Natl Acad Sei USA 78: 5137–5141Google Scholar
  466. Weiss HJ (1974) Relation of von Willebrand factor to bleeding time. N Engl J Med 291: 420PubMedGoogle Scholar
  467. Weiss HJ (1975) Abnormalities of factor VIII and platelet aggregation-use of ristocetin in diagnosing the von Willebrand syndrome. Blood 45: 403–412PubMedGoogle Scholar
  468. Weiss HJ (1977) von Willebrand’s disease. In: Williams WJ, Beutler E, Ersley EJ, Rundles RW (eds) Hematology. McGraw-Hill, New York, p 1434Google Scholar
  469. Weiss HJ, Hoyer LW (1973) von Willebrand factor: Dissociation from antihemophilic factor procoagulant activity. Science 182: 1149–1151Google Scholar
  470. Weiss HJ, Kochwa S (1970) Molecular forms of antihaemophilic globulin in plasma, cryoprecipitate and after thrombin activation. Br J Haematol 18: 89–100PubMedGoogle Scholar
  471. Weiss HJ, Rogers J (1972) Correction of the platelet abnormality in von Willebrand’s disease by cryoprecipitate. Am J Med 53: 734PubMedGoogle Scholar
  472. Weiss HJ, Phillips LL, Rosner W (1972) Separation of subunits of antihemophilic factor ( AHR) by agarose gel chromatography. Thromb Diath Haemorrh 27: 212–219Google Scholar
  473. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J (1973a) Quantitative assay of a plasma factor deficient in von Willebrand’s disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 52: 2708–271Google Scholar
  474. Weiss HJ, Rogers J, Brand H (1973 b) Defective ristocetin-induced platelet aggregation in von Willebrand’s disease and its correction by factor VIII. J Clin Invest 52: 2697–2707Google Scholar
  475. Weiss HJ, Tschopp TB, Baumgartner HR (1974) Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med 57: 920–925Google Scholar
  476. Weiss HJ, Sussmann II, Hoyer LW (1977) Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest 60: 390–404PubMedGoogle Scholar
  477. Weiss HJ, Baumgartner HR, Tschopp TB (1978 a) Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand’s disease. Blood 51: 267–279Google Scholar
  478. Weiss HJ, Turitto VT, Baumgartner HR ( 1978 b) Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear dependent decrease of adhesion in von Willebrand’s disease and the Bernard-Soulier syndrome. J Lab Clin Med 92: 750–764Google Scholar
  479. Weiss HJ, Ball AP, Mannucci PM (1982 a) Incidence of severe von Willebrand’s disease. N Engl J Med 307:127 (letter)Google Scholar
  480. Weiss HJ, Meyer D, Rabinowitz R (1982b) Pseudo von Willebrand’s disease: An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high molecular weight multimers. N Engl J Med 306: 326–333Google Scholar
  481. WHO Expert Committee (1977) Methods for the detection of haemophilia carriers: A memorandum. Bull WHO 55: 675Google Scholar
  482. Willebrand EA von (1926) Hereditär pseudohamofili. Finska laeksaellsk handl 68: 87–112Google Scholar
  483. Willebrand EA von (1931) Ueber hereditaere Pseudohaemophilie. Acta Med Scand 76: 521–550Google Scholar
  484. Willebrand EA von, Jürgens R (1933 a) Über eine neue Bluterkrankheit, die konstitutionelle Thrombopathie. Klin Wochenschr 12: 414Google Scholar
  485. Willebrand EA von, Jürgens R (1933b) Über ein neues und vererbbares Blutungsübel: Die konstitutionelle Thrombopathie. Dtsch Arch Klin Med 175: 453Google Scholar
  486. Winckelmann G, Böttcher D (1980) Die Ristocetin induzierte Plättchenaggregation in der Diagnostik des von Willebrand Syndroms. In: Voss H von, Göbel U (Hrsg) Praktische Anwendung der Thrombozytenfunktionsdiagnostik. Thieme, Stuttgart, S 151Google Scholar
  487. Winckelmann G, Groh R, Schneider J, Huber P (1967) Schwangerschaft und Entbindung bei Patientinnen mit einem von Willebrand-Jürgens-Syndrom. Verhalten des Faktor VIII (antihämophilen Globulin). Dtsch Med Wochenschr 92: 436Google Scholar
  488. Zettervall O, Nilsson IM (1978) Acquired von Willebrand’s disease caused by monoclonal antibody. Acta Med Scand 204: 521PubMedGoogle Scholar
  489. Zimmerman TS, Roberts JR (1980) Factor VHI-related antigen, In: Nakamura RM, Dito WR, Tucker ES III (eds) Immunoassays. Clinical laboratory techniques for the 1980s. Alan R Liss, New YorkGoogle Scholar
  490. Zimmerman TS, Ruggeri ZM (1982) Von Willebrand’s disease. Prog Hemost Thromb 6: 203–236PubMedGoogle Scholar
  491. Zimmerman TS, Ruggeri ZM (1983) Von Willebrand’s disease. Clin Haematol 12: 175–200PubMedGoogle Scholar
  492. Zimmerman TS, Ratnoff OD, Powell AE (1971) Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease. J Clin Invest 50: 244 — 254PubMedGoogle Scholar
  493. Zimmerman TS, Hoyer LW, Dickson L, Edgington TS (1975 a) Determination of the von Willebrand’s disease antigen (factor VHI-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med 86: 152–159Google Scholar
  494. Zimmerman TS, Roberts J, Edgington TS ( 1975 b) Factor VHI-related antigen. Multiple molecular forms in human plasma. Proc Natl Acad Sei USA 72: 5121–5125Google Scholar
  495. Zimmerman TS, Abildgaard C, Meyer D (1979 a) The factor VIII abnormality in severe von Willebrand’s disease. N Engl J Med 301: 1307–1310Google Scholar
  496. Zimmerman TS, Voss R, Edgington TS (1979b) Carbohydrate of factor VIII/von Willebrand factor in von Willebrand’s disease. J Clin Invest 64: 1298–1302PubMedGoogle Scholar
  497. Zimmerman TS, Roberts JR, Ruggeri ZM (1982) Factor VHI-related antigen: Characterization by electrophoretic techniques. In: Bloom AL (ed) The hemophilias, methods in hematology, vol 5. Churchill Livingstone, Edinburgh London Melbourne New York, pp 81–91Google Scholar
  498. Zucker MB, Kim SJA, McPherson J, Grant RA (1977) Binding of factor VIII to platelets in the presence of ristocetin. Br J Haematol 35: 535PubMedGoogle Scholar
  499. Zucker MB, Broeckman MJ, Kaplan KL (1979) Factor VHI-related antigen in human blood platelets. Localization and release by thrombin and collagen. J Lab Clin Med 94: 675–682Google Scholar
  500. Zuzel M, Nilsson IM, Aberg M (1978) A method for measuring plasma ristocetin cofactor activity. Thromb Res 12: 745–75PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

There are no affiliations available

Personalised recommendations